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Abstract: Die Rheumatoid Arthritis (RA) ist eine chronische Autoimmunerkrankung mit fortschreitender
Zerstörung der Gelenke. In der Pathogenese der Erkrankung spielen zwei zelluläre Kompartimente eine
wesentliche Rolle. Das eine beinhaltet aktivierte Immunzellen wie T-Zellen, B-Zellen und Makropha-
gen. Kennzeichnend für diese Gruppe ist das Freisetzen von entzündlichen Botenstoffen (Zytokine)
wie Interleukin (IL)- 1 beta, IL-6 und „tumor-necrosis-factor“ (TNF) alpha sowie Autoantikörpern von
Plasmazellen. Das andere umfasst die aktivierten synovialen Fibroblasten (RASF), Osteoklasten und
Chondrozyten, alles Effektorzellen, die durch Aktivierung zur Zerstörung der Gelenke beitragen. Bis
heute konnte kein genetischer Polymorphismus aufgezeigt werden, der den aktivierten Phänotyp dieser
synovialer Fibroblasten ausreichend erklärt. Unsere Hypothese ist, dass epigenetische Modifikationen,
insbesondere veränderte DNA Methylierung zur Aktivierung dieser Zellen beitragen und so die Zer-
störung von Knorpel- und Knochensubstanz herbeiführen. Wir zeigen hier erstmalig eine Untersuchung
des Methylierungsmusters synovialer Fibroblasten von Patienten mit RA. In in vivo Untersuchungen
wiesen synoviale Gewebe von Patienten mit RA eine signifikante Hypomethylierung in den untersuchten
Zellkernen auf im Vergleich zu Geweben von Patienten mit Osteoarthritis (OA). Und das betrifft ins-
besondere die synovialen Fibroblasten wie bei in vitro Untersuchungen isolierter Zellkerne gezeigt wer-
den konnte (Chapter 2, Figure 1). Inflammatorische Zytokine wie TNF alpha und IL-1 beta hatten
einen positiven Einfluss auf den Zellzyklus und gleichzeitig führten sie zu einer reduzierter Menge an 5-
Methylcytosin in den Zellkernen der untersuchten Zellen. Wir zeigen hier eine reduzierte Expression von
DNA-Methyltransferase 1 (DNMT1) in RASF, die möglicherweise zur progressiven Hypomethylierung
dieser Zellen beiträgt. In diesem Zusammenhang unterstützen proinflammatorische Zytokine den Prozess
der DNA Hypomethylierung durch Aktivierung der Zellproliferation, sie sind aber nicht die Ursache des
niedrigen basalen Levels an DNMT1 in RASF. Darüber hinaus konnten wir aufzeigen, dass repetitive
Sequenzen wie LINE-1 in RASF demethyliert sind, was die Hypothese einer globalen Hypomethylierung
in RASF unterstützt. Um die für den aktivierten Phänotyp synovialer RA Fibroblasten verantwortlichen
Gene zu identifizieren, wurden synoviele Fibroblasten von gesunden Probanden über einen Zeitraum von
2 Monaten mit nicht toxischen Mengen des DNMT1-Inhibitors 5-azacytidine (5-azaC) behandelt, und
anschießend eine Genexpressionsanalyse durchgeführt. Wir konnten zeigen, dass mehr als die Hälfte
der so überexprimierten Gene mit denen übereinstimmen, die mit der Pathogenese der RA assoziiert
wurden. Dies sind Gene, die zur Gelenkzerstörung beitragen wie Matrix-Metalloproteinasen (MMPs),
Integrine und viele weitere, die im Kapitel 2 aufgeführt sind (Suppl. Tables 1,2). In Kapitel 3 zeigen
wir die Untersuchung eines spezifischen Gens mit verändertem Methylierungsmuster in RASF. Aktivierte
RASF exprimieren unterschiedliche Chemokine, die so weitere Immunzellen in die betroffenen Gelenke
locken. CXCL12 (SDF-1￿) ist eines dieser Chemokine, welches in RASF überexprimiert wird. Wir kon-
nten nachweisen, dass im Vergleich zu OASF, in RASF der Promotor von CXCL12 weniger methyliert
ist. Weiterhin korrelierte die Expression von CXCL12 auf mRNA Level in diesen Zellen signifikant mit
der Hypomethylierung im CXCL12 Promotor. Die durch Hypomethylierung verstärkte Expression von
CXCL12 in RASF induzierte dann in den Zellen eine verstärkte Expression von MMPs durch die Bindung
an den dazugehörigen Rezeptor CXCR7. Wir beschreiben hier einen endogenen Aktivierungsmechanismus
in RASF, der zur progressiven Zerstörung der Gelenke beiträgt. Basierend auf unserer Daten verursacht
eine veränderte globale und genspezifische DNA Methylierung den aktivierten invasiven Phänotyp der
RASF. Summary Rheumatoid arthritis is a chronic autoimmune disease involving destruction of affected
joints. Two cellular compartments are involved in the pathogenesis of RA. The first one involves acti-
vated T cells, B cells and macrophages. They secrete a variety of pro-inflammatory cytokines such as
interleukin- 1beta, IL-6 and tumor necrosis factor alpha (TNFalpha) as well as a variety of autoanti-
bodies. The second compartment involves activated rheumatoid arthritis synovial fibroblasts (RASF),
osteoclasts and chondrocytes that are the effector cells of joint destruction. The thesis focuses on the epi-
genetic mechanisms leading to the activated phenotype of RASF. Since to date no genetic polymorphism
can explain the hyperactive phenotype of synovial fibroblasts, we hypothesised that epigenetic modifica-
tions, particularly impaired DNA methylation, can cause the activation of synovial fibroblasts and lead
to joint destruction. For the first time, the methylation status of cells was analysed in the synovium of
patients with rheumatoid arthritis (RA). RA synovial tissues were found to have hypomethylated nuclei
(Chapter 2, Figure 1). Especially RASF had low amounts of 5-methylcytosine. Pro-inflammatory cy-
tokines such as TNF alpha and IL-1 beta induced cell cycle progression and reduced further the amount
of 5-methylcytosine in the nuclei. We reported a deficiency of DNA methyltransferase 1 (DNMT1) in
RASF that can be an important factor involved in the progressive demethylation. In this context, pro-
inflammatory cytokines favor DNA hypomethylation by increasing the rate of cell proliferation; however,
they were not responsible for low basal levels of DNMT1. Furthermore, repetitive sequences such as
LINE-1 were demethylated in RASF, supporting the hypothesis of an active global hypomethylation in
these cells. To mimic the chronic hypomethylation state of synovial fibroblasts and identify gene targets,
normal synovial fibroblasts were treated over a long period of time (2 months) with a non-toxic dose of
the DNMT1 inhibitor 5- azacytidine (5-azaC) and a gene expression analysis was performed. More than
half of the genes that were found to be overexpressed by this treatment were previously associated with
the pathogenesis of RA. These included genes associated with joint destruction such as matrix metal-
loproteinases (MMPs), integrins and others summarized in Chapter 2 (Suppl. Tables 1,2). Finally, a
specific gene target that may have an impaired DNA methylation in RASF was analysed in Chapter 3.
Activated RASF secrete chemokines that attract a variety of inflammatory cells into the joint. CXCL12
(SDF-1￿) is a chemokine overexpressed and secreted by RASF. We reported that the promoter of CXCL12
is less methylated in RASF than in osteoarthritis synovial fibroblasts (OASF). The mRNA expression of
CXCL12 significantly correlated with the CXCL12 promoter methylation. The upregulation of CXCL12
could stimulate RASF to produce more MMPs via the receptor CXCR7. Thereby, we describe an endoge-
nously activated pathway in RASF which promotes joint destruction. In conclusion, this study confirms
the hypothesis that global and gene specific DNA methylation alterations are responsible for the activated
phenotype of RASF.
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Zusammenfassung 
 
Die Rheumatoid Arthritis (RA) ist eine chronische Autoimmunerkrankung mit 
fortschreitender Zerstörung der Gelenke. In der Pathogenese der Erkrankung spielen zwei 
zelluläre Kompartimente eine wesentliche Rolle. Das eine beinhaltet aktivierte Immunzellen 
wie T-Zellen, B-Zellen und Makrophagen. Kennzeichnend für diese Gruppe ist das Freisetzen 
von entzündlichen Botenstoffen (Zytokine) wie Interleukin (IL)- 1 beta, IL-6 und „tumor-
necrosis-factor“ (TNF) alpha sowie Autoantikörpern von Plasmazellen. Das andere umfasst 
die aktivierten synovialen Fibroblasten (RASF), Osteoklasten und Chondrozyten, alles 
Effektorzellen, die durch Aktivierung zur Zerstörung der Gelenke beitragen. 
 
Bis heute konnte kein genetischer Polymorphismus aufgezeigt werden, der den aktivierten 
Phänotyp dieser synovialer Fibroblasten ausreichend erklärt. Unsere Hypothese ist, dass 
epigenetische Modifikationen, insbesondere veränderte DNA Methylierung zur Aktivierung 
dieser Zellen beitragen und so die Zerstörung von Knorpel- und Knochensubstanz 
herbeiführen.  
 
Wir zeigen hier erstmalig eine Untersuchung des Methylierungsmusters synovialer 
Fibroblasten von Patienten mit RA. In in vivo Untersuchungen wiesen synoviale Gewebe von 
Patienten mit RA eine signifikante Hypomethylierung in den untersuchten Zellkernen auf im 
Vergleich zu Geweben von Patienten mit Osteoarthritis (OA). Und das betrifft insbesondere 
die synovialen Fibroblasten wie bei in vitro Untersuchungen isolierter Zellkerne gezeigt 
werden konnte (Chapter 2, Figure 1). 
 
Inflammatorische Zytokine wie TNF alpha und IL-1 beta hatten einen positiven Einfluss auf 
den Zellzyklus und gleichzeitig führten sie zu einer reduzierter Menge an 5-Methylcytosin in 
den Zellkernen der untersuchten Zellen. Wir zeigen hier eine reduzierte Expression von DNA-
Methyltransferase 1 (DNMT1) in RASF, die möglicherweise zur  progressiven 
Hypomethylierung dieser Zellen beiträgt. In diesem Zusammenhang unterstützen 
proinflammatorische Zytokine den Prozess der DNA Hypomethylierung durch Aktivierung 
der Zellproliferation, sie sind aber nicht die Ursache des niedrigen basalen Levels an DNMT1 
in RASF. Darüber hinaus konnten wir aufzeigen, dass repetitive Sequenzen wie LINE-1 in 
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RASF demethyliert sind, was die Hypothese einer globalen Hypomethylierung in RASF 
unterstützt.  
 
Um die für den aktivierten Phänotyp synovialer RA Fibroblasten verantwortlichen Gene zu 
identifizieren, wurden synoviele Fibroblasten von gesunden Probanden über einen Zeitraum 
von 2 Monaten mit nicht toxischen Mengen des DNMT1-Inhibitors 5-azacytidine (5-azaC) 
behandelt, und anschießend eine Genexpressionsanalyse durchgeführt. Wir konnten zeigen, 
dass mehr als die Hälfte der so überexprimierten Gene mit denen übereinstimmen, die mit der 
Pathogenese der RA assoziiert wurden. Dies sind Gene, die zur Gelenkzerstörung beitragen 
wie Matrix-Metalloproteinasen (MMPs), Integrine und viele weitere, die im Kapitel 2 
aufgeführt sind (Suppl. Tables 1,2). 
 
In Kapitel 3 zeigen wir die Untersuchung eines spezifischen Gens mit verändertem 
Methylierungsmuster in RASF. Aktivierte RASF exprimieren unterschiedliche Chemokine, 
die so weitere Immunzellen in die betroffenen Gelenke locken. CXCL12 (SDF-1α) ist eines 
dieser Chemokine, welches in RASF überexprimiert wird. Wir konnten nachweisen, dass im 
Vergleich zu OASF, in RASF der Promotor von CXCL12 weniger methyliert ist. Weiterhin 
korrelierte die Expression von CXCL12 auf mRNA Level in diesen Zellen signifikant mit der 
Hypomethylierung im CXCL12 Promotor. Die durch Hypomethylierung verstärkte 
Expression von CXCL12 in RASF induzierte dann in den Zellen eine verstärkte Expression 
von MMPs durch die Bindung an den dazugehörigen Rezeptor CXCR7.  
 
Wir beschreiben hier einen endogenen Aktivierungsmechanismus in RASF, der zur 
progressiven Zerstörung der Gelenke beiträgt. Basierend auf unserer Daten verursacht  eine 
veränderte globale und genspezifische DNA Methylierung den aktivierten invasiven Phänotyp 
der RASF. 
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Summary  
 
Rheumatoid arthritis is a chronic autoimmune disease involving destruction of affected joints. 
Two cellular compartments are involved in the pathogenesis of RA. The first one involves 
activated T cells, B cells and macrophages. They secrete a variety of pro-inflammatory 
cytokines such as interleukin-1beta, IL-6 and tumor necrosis factor alpha (TNFalpha) as well 
as a variety of autoantibodies. The second compartment involves activated rheumatoid 
arthritis synovial fibroblasts (RASF), osteoclasts and chondrocytes that are the effector cells 
of joint destruction. The thesis focuses on the epigenetic mechanisms leading to the activated 
phenotype of RASF. 
 
Since to date no genetic polymorphism can explain the hyperactive phenotype of synovial 
fibroblasts, we hypothesised that epigenetic modifications, particularly impaired DNA 
methylation, can cause the activation of synovial fibroblasts and lead to joint destruction. For 
the first time, the methylation status of cells was analysed in the synovium of patients with 
rheumatoid arthritis (RA). RA synovial tissues were found to have hypomethylated nuclei 
(Chapter 2, Figure 1). Especially RASF had low amounts of 5-methylcytosine. Pro-
inflammatory cytokines such as TNF alpha and IL-1 beta induced cell cycle progression and 
reduced further the amount of 5-methylcytosine in the nuclei. We reported a deficiency of 
DNA methyltransferase 1 (DNMT1) in RASF that can be an important factor involved in the 
progressive demethylation. In this context, pro-inflammatory cytokines favor DNA 
hypomethylation by increasing the rate of cell proliferation; however, they were not 
responsible for low basal levels of DNMT1. Furthermore, repetitive sequences such as LINE-
1 were demethylated in RASF, supporting the hypothesis of an active global hypomethylation 
in these cells. To mimic the chronic hypomethylation state of synovial fibroblasts and identify 
gene targets, normal synovial fibroblasts were treated over a long period of time (2 months) 
with a non-toxic dose of the DNMT1 inhibitor 5-azacytidine (5-azaC) and a gene expression 
analysis was performed. More than half of the genes that were found to be overexpressed by 
this treatment were previously associated with the pathogenesis of RA. These included genes 
associated with joint destruction such as matrix metalloproteinases (MMPs), integrins and 
others summarized in Chapter 2 (Suppl. Tables 1,2).  
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Finally, a specific gene target that may have an impaired DNA methylation in RASF was 
analysed in Chapter 3. Activated RASF secrete chemokines that attract a variety of 
inflammatory cells into the joint. CXCL12 (SDF-1α) is a chemokine overexpressed and 
secreted by RASF. We reported that the promoter of CXCL12 is less methylated in RASF 
than in osteoarthritis synovial fibroblasts (OASF). The mRNA expression of CXCL12 
significantly correlated with the CXCL12 promoter methylation. The upregulation of 
CXCL12 could stimulate RASF to produce more MMPs via the receptor CXCR7.  
 
Thereby, we describe an endogenously activated pathway in RASF which promotes joint 
destruction. In conclusion, this study confirms the hypothesis that global and gene specific 
DNA methylation alterations are responsible for the activated phenotype of RASF. 
 
 
Abbreviations 
 
 
8
Abbreviations 
 
 
5-azaC   5- azacytidine 
5-MeC  5-methylcytosine 
Anti-CCP  anti-cyclic citrullinated peptide 
AP-1   activator protein 1 
cDNA   complementary DNA 
CK   cathepsin K 
CRP    C-reactive protein  
CXCL12   chemokine (C-X-C motif) ligand 12 (SDF-1) 
dCt   delta Ct 
DMARDs   disease modifying antirheumatic drugs 
DNMT-1 DNA methyltransferase 1 
FACS    fluorescence activated cell sorting 
HDAC  histone deacetylases 
HPLC  high Performance Liquid Chromatography 
ICF  immunodeficiency, centromere instability and facial anomalities syndrome. 
ICR   imprinting control region 
IL-1β   interleukin 1 beta 
MeCP2  methylated CpG binding protein 2 
MMP    matrix metalloproteinases 
MTX   methotrexate 
NSAIDs  nonsteroidal anti-inflammatory drugs 
NSF   normal synovial fibroblasts 
OA   osteoarthritis 
ORF1    open reading frame 1 
PCNA  proliferating cell nuclear antigen 
PCR    polymerase chain reaction 
PDGF   platelet derived growth factor 
RA  rheumatoid arthritis 
RASF   rheumatoid arthritis synovial fibroblasts 
RFs   rheumatoid factors 
SAM     S-adenosylmethionine 
Abbreviations 
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SCID mice  severe combined immunodeficiency mice 
SDF-1   stromal derived factor 1 (CXCL12) 
SF                     synovial fibroblasts 
siRNA              small interfering RNA  
TNFα    tumor necrosis factor alpha 
TSA   trichostatin A 
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Chapter  1: Introduction 
 
 
 
 
 
 
 
 
 
 
The introduction is adapted from the following publications and books: 
 
Karouzakis E., Gay R.E., Gay S., Neidhart M. Epigenetic deregulation in rheumatoid arthritis. 
Advances in Experimental Medicine and Biology 2011; 711:137-149. 
 
Karouzakis E., Gay R.E., Gay S., Neidhart M. Epigenetic control in rheumatoid arthritis 
synovial fibroblasts. Nature Reviews Rheumatology 2009; 5(5):266-72. 
 
Karouzakis E., Jüngel A., Gay R.E., Kolling C., Gay S., Neidhart M. Epigenetic approaches 
to the study of the pathogenesis of rheumatic diseases. European Musculoskeletal Review 
2008; 3:41-43. 
 
Karouzakis E., Neidhart M., Gay R.E., Gay S. Molecular and cellular basis of rheumatoid 
arthritis joint destruction. Immunology Letters 2006; 106(1):8-13. 
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Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder of unknown etiology 
that is associated with progressive joint destruction. RA is described as an autoimmune 
disease and is characterised by polyarticular pain, swelling, morning stiffness, malaise and 
fatigue. The disease does not have specific features and develops over a long period of time. 
Arthritis affects the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints of 
both hands. This symmetry is the most characteristic early clinical feature. Classification 
criteria for RA were drafted in 1956 by the American College of Rheumatology (ACR) and 
revised in 1987 in order to provide guidelines for clinical trials [1]. Also, rheumatologists, in 
order to assess the effect of different medications in the treatment of RA, developed the ACR 
scoring system. ACR 20 means 20 % improvement based on a scale that includes number of 
affected joints, inflammatory markers, pain and disability scoring. Terms like “ACR 20”, 
“50” or “70” which mean 20% to 70 % significant improvement obtained with a given drug 
are usually found in the literature. 
 
1. Etiology [adapted from Karouzakis E. et al. Immunology Letters 2006; 106(1):8-13, and 
Kelley's Textbook of Rheumatology; 2009] 
 
RA affects 0.8-1.0 % of the population [2]. RA appears less common in Asia and Africa than 
in United States and Europe. In young adults, the disease is predominantly found in women. 
Men are less affected than women, but the occurrence of the disease increases with age and 
reaches the same proportion between genders in the elderly. The etiology of RA remains still 
unknown. It has been hypothesised that infectious agents such as viruses and bacteria cause a 
chronic inflammatory response that targets components of the joint [3]. 
Different research data showed evidence of autoimmunity, the most obvious being the 
production of autoantibodies and the association with specific HLA subtypes. Thus, the 
genetic predisposition to RA of individuals with HLA-DRB1 “shared epitope” has raised the 
possibility of a specific autoantigen that triggers a T cell clonal response [4]. The 
susceptibility to RA is associated with the epitope glutamine-leucine-arginine-alanine-alanine 
(QKRAA) that is found in HLA-DR4, DR14 and some DR1beta chains. However, 
experiments that tried to elute peptides from the pocket of this RA susceptibility allele did not 
reveal a specific antigen for RA. The shared epitope might be not the most important and is 
certainly not a unique risk factor for RA. Thus, in large studies of patients with 
undifferentiated inflammatory arthritis, the progression to RA occurred regardless of the 
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HLA-DR genotype. On the other hand, about 50% of RA patients are positive for anti-cyclic 
citrullinated peptide (anti-CCP) autoantibodies. Patients with the susceptibly HLA-DR 
phenotype and with anti-CCP antibodies develop a disease with greater severity. Further 
research regarding the genetic influence on the disease led to the investigation of single 
nucleotide polymorphisms in the promoter regions of various genes. Several polymorphisms 
have been described for inflammatory cytokines and chemokines including tumor necrosis 
factor alpha (TNF, interleukin-1beta (IL-1 and RANTES. Gene polymorphisms that are 
independent from HLA genotype and pro-inflammatory cytokine levels are peptidyl arginase 
deiminase (PADI) and PTPN22 [5, 6]. PADI genes include four alleles (PADI1 to PADI4) 
and PADIs are responsible for the post-translation modification of arginine to citrulline. 
PTPN22 is responsible for the phosphorylation status of several kinases that have important 
roles in T cell activation. 
Environmental factors, such as smoking, have also been implicated in the development of RA. 
The influence of smoking is not clearly known [7]. Smoking increases the risk of developing 
anti-CCP antibodies in carriers of the HLA-DR shared epitope [8].  
Examination of ancient skeletons in Europe failed to detect the onset of RA until end of the 
18th century with the beginning of industrialisation. In contrast, RA was evident in Native 
Americans thousands of years ago. A possible hypothesis is that the disease migrated from the 
New World to the Old World with trading, exploration trips and wars. Perhaps an infectious 
agent was responsible for the propagation. Indeed, different infectious agents have been 
associated to the pathogenesis of RA, including mycobacteria, E. coli, Epstein Barr virus, 
parvovirus and retroviruses [9]. These infectious agents could be involved in the phenomenon 
of molecular mimicry or in the alteration of the activity of cells involved in innate and 
adaptive immunity.  
 
2. Pathogenesis [adapted from Karouzakis E. et al. Immunology Letters 2006; 106(1):8-13, 
Kelley's Textbook of Rheumatology; 2009] 
 
RA is a disease of the musculoskeletal system. Synovial joints are mainly affected by the 
disease. A typical example of a normal synovial joint is shown in Figure 1. Characteristic 
structures include two bones joined by a fibrous capsule and ligaments to support the joint. 
The synovial membrane or synovium is located in the inner part of the fibrous capsule and 
surrounds the joint everywhere, except the articular cartilage. The inner surface of the 
membrane is usually smooth and folded into numerous processes called villi. The synovium is 
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abundantly supplied with blood vessels, nerves, and lymphatics; it provides immunological 
protection and produces synovial fluid. The synovial membrane consists of two cell types: 
synovial fibroblasts (SF) and macrophages. The SF produce a long chain sugar polymer called 
hyaluronan that is a component of the synovial fluid together with a molecule called lubricin, 
which lubricates the joint surfaces. The synovial fluid provides a liquid environment for the 
joint surfaces and nutrients for chondrocytes enclosed in the cartilage. The healthy hyaline 
cartilage is a connective tissue consisting of proteoglycans, collagen, glycoproteins and water. 
Chondrocytes are the specialised cells for the homeostasis of cartilage. The macrophages 
guard the synovial fluid from pathogens. 
                 
 
 
Figure 1: Characteristics of a knee synovial joint in normal conditions and rheumatoid 
arthritis (RA) patients [retrieved from the web site of Prof. Michel Neidhart-
http://epigenetics.ch].  
 
In RA, the synovial tissue is hypertrophic and inflamed. It contains diverse cell populations, 
including T cells, B cells, macrophages, dendritic cells, neutrophils, mast cells and SF. 
Microscopic examination of synovial tissues from patients with RA showed that there is an 
increased thickness of the synovial lining and an infiltration of cells around small blood 
vessels, leading to the characteristic sign of synovial hyperplasia. The rheumatoid endothelial 
cells have an altered function and express various adhesion molecules that facilitate the entry 
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of cells into the tissue. Memory T lymphocytes (CD4+, CD45RO+) are the major infiltrating 
cells in the rheumatoid synovium [10]. They are found in close proximity with dendritic cells, 
SF and macrophages and secrete Th1-like pro-inflammatory cytokines, such as interferon-
gamma (INFγ).  
 
As a result of continuous T cell activation and cytokine secretion, macrophages are in turn 
activated and release TNFα and IL-1β [11]. These pro-inflammatory cytokines activate SF to 
secrete cartilage degrading enzymes, such as matrix metalloproteinases (MMPs). 
 
Activated B cells produce a number of autoantibodies, such as rheumatoid factors (RFs) and 
anti-CCP autoantibodies in the synovium. RFs are typically immunoglobulins (Ig)M 
antibodies that bind the Fc fragment of IgGs. They are considered a late marker of the disease 
and appear in the sera of 70-80% of patients with RA. Autoantibodies to CCP have been 
identified as markers for RA. Interestingly, these autoantibodies can be detected several years 
before the onset of the disease [12]. Autoantibodies, in particular RFs, form immune 
complexes that can activate, complement and increase inflammation. Patients with RA 
develop germinal centre structures in the synovial tissue [13].  
 
In addition, an increased number of mast cells have also been found in the rheumatoid 
synovium and shown to release granules that contribute to ongoing inflammation. Osteoclasts 
are also found at sites of bone destruction. They are derived from myelomonocytic precursor 
cells with the help of T cells and SF that express the receptor activator of NFkB ligand 
(RANKL) [14]. Lymphocytes, macrophages, SF and osteoclasts secrete a large variety of 
products that cause the pathological features of rheumatoid synovium including inflammation, 
hyperplasia, infiltration, activation, proliferation, as well as cartilage and bone destruction 
[15]. 
 
3. Treatment [adapted from Kelley's Textbook of Rheumatology; 2009] 
 
Most therapies today are based on the use of Nonsteroidal Anti-inflammatory Drugs 
(NSAIDs), Disease Modifying Antirheumatic Drugs (DMARDs) and biologic agents which 
mainly target the chronic inflammation [16].  
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NSAIDs have the ability to suppress the synthesis of prostaglandins by inhibiting the 
cyclooxygenase enzymes (COX-1 and COX-2). The expression of these enzymes is induced 
during inflammation. The most popular DMARD drug for RA treatment is methotrexate. At 
low doses, it has immunomodulatory and anti-inflammatory effects. Also, another successful 
DMARD drug is leflunomide that inhibits the synthesis of pyrimidines and effects T cell 
proliferation. 
 
Monoclonal antibodies such as Infliximab and Adalimumab as well as soluble receptors like 
Etanercept that inhibit TNFα, have been used successfully in the treatment of RA [17]. In 
addition, Abatacept is a recombinant CTLA4Ig that downregulates T cell activation by 
interfering with T cell signalling [18]. Also, therapies targeting the B cells have been 
exploited. Clinical trials with Rituximab (anti-CD20) have shown some impressive results in 
the treatment of RA [19]. 
 
However, the biological therapies mentioned above which target only the immune system 
cells do not have an ACR 70 response over 60%. All current therapies ignore the role of 
synovial fibroblasts in the pathogenesis of RA.  
 
4. Activated rheumatoid arthritis synovial fibroblasts [adapted from Karouzakis E. et al. 
Immunology Letters 2006; 106(1):8-13, and Karouzakis E. et al. Nature Reviews 
Rheumatology 2009; 5(5): 266-72] 
 
Rheumatoid arthritis synovial fibroblasts (RASF) are mainly found in the synovial sublining 
of joints which is multilayered and hyperplastic. Activated RASF display an aggressive and 
invasive behaviour that resembles those of metastatic cancer cells (Figure 3). They have 
characteristic morphological features such as a round shape and a large pale nuclei with 
prominent nucleoli [20]. The most characteristic functional feature is the ability of RASF to 
adhere to cartilage and to initiate the degradation of extracellular matrix (ECM) components. 
Many observations support the notion that the activated phenotype of RASF is an intrinsic 
property of these cells. The clearest evidence came from an animal model using severe 
combined immunodeficiency mice (SCID) in our laboratory [21]. In this model, SFs were 
implanted together with human cartilage under the renal capsule of SCID mice for 60 days. 
During this period, RASF attached to and invaded the cartilage in a similar way as observed 
in the human joints. Most important is the fact that the invasion of RASF occured without any 
support from the immune system. A recent study using a similar model has further proposed 
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that RASF are able to migrate from an affected joint to a distant healthy joint and are 
responsible for the symmetrical distribution of the disease [22, 23]. Indeed, the RA synovial 
fluid contains “floating” fibroblast-like cells that are able to destroy cartilage. This is not 
found in other joint diseases, such as osteoarthritis (OA) [24]. 
 
Synovial hyperplasia could be due to an increased rate of proliferation of the RASF. This 
concept is supported by the increased expression of transcription factors, markers of 
proliferation and growth factors, including platelet derived growth factor (PDGF), basic 
fibroblast growth factor (bFGF) and transforming growth factor beta (TGFbeta) [25-28]. 
Proto-oncogenes including ras, myc, myb involved in the regulation of the cell cycle, 
transcriptional regulation, or acting as growth factors in a variety of cells are expressed 
abundantly in RASF, especially at sites of invasion [29]. Macrophage inhibitory factor (MIF) 
has been shown to cause the proliferation of RASF through the ERK MAP kinase pathway 
[30]. MIF knock out mice revealed a reduced rate of proliferation and high p53 expression 
[31]. However, RASF did not proliferate more than other SF in vitro. In addition, Seemayer et 
al. and Kunzler et al. provide evidence that the invasive behaviour of RASF cell is 
independent from their proliferation [32, 33]. 
 
Another property of the RASF that might contribute to synovial hyperplasia is the decreased 
rate of apoptosis [34], especially at sites of synovial invasion into cartilage and bone. 
Although Fas ligands are present in synovial fluid, the cells appear resistant to apoptosis [35]. 
Several studies have examined the expression of anti-apoptotic molecules in RASF. FLICE 
like inhibitory protein (FLIP) is expressed by RASF at sites of invasion into cartilage and 
bone [36]. It can inhibit the pro-caspase 8 and interfere with the apoptosis signalling pathway. 
FLIP expression is induced by TNF and siRNA silencing of FLIP sensitises the cells to 
apoptosis [37].RASF express high levels of SUMO-1 protein that protects the cells from 
apoptosis [38]. A recent study suggested that SUMO-1 inhibits apoptosis in RASF indirectly 
by modifying the nuclear promyelocytic leukemia (PML) that traps the pro-apoptotic 
molecule DAXX in the PML nuclear bodies [39]. Moreover, the stimulation of RASF with 
MIF reduces the rate of apoptosis in RASF. MIF knock out mice have reduced severity of 
antigen induced arthritis due to high expression of p53 and apoptosis in the synovium [31]. 
Furthermore, the novel molecule synoviolin, an E3 ubiquitin ligase, has been described as 
another important regulator of proliferation and apoptosis in RA [40].  
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Thus, both proliferation and resistance to apoptosis appear to contribute to the synovial 
hyperplasia in RA. It is important to note, however, that it is currently thought that the 
migration of inflammatory cells into the synovial tissue predominantly contributes to this 
hyperplasia. 
 
Activated RASF maintain the ongoing local inflammatory immune response in the joint 
(Figure 2). The production and secretion of interleukin-15, -16, -17 and CXCL12 /SDF-1α 
(stromal cell derived factor 1 ) from RASF appear in great part responsible for T cell 
activation [41, 42]. In addition, CXCL12 may promote neoangiogenesis. CXCL13 has been 
shown to promote the migration of B cells into the synovium [43, 44]. In turn, B cells express 
cytokines such as lymphotoxins  and , which activate follicular dendritic cells, attract T 
cells and further organise the germinal centers. In addition, RASF show a hyperreactive 
response to the proinflamamtory cytokines TNFα and IL-1β. The activation characteristics of 
RASF are dependent on multiple transcription factors such as Nuclear Factor-kβ (NF-kβ) and 
Activator protein-1 (AP1), the p38 stress activated MAP kinases (MAPK) and PI-3 kinase. 
These signalling pathways in RASF reflect the maintenance of a chronic pro-inflammatory 
cytokine milieu in the synovium that in turn triggers the production of catabolic enzymes.  
 
 
 
 
Figure 2: Interaction between cells of the immune system and synovial fibroblasts mediating 
joint destruction [adapted from Karouzakis E. et al. Immunology Letters 2006; 106(1):8-13] 
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The expression of members of the interleukin-6 family such as IL-11, leukemia inhibitory 
factor (LIF) and oncostatin M (OSM) are expressed by RASF at the site of invasion [45]. 
Another critical modulator of inflammation is prostaglandin E2 (PGE2). RASF secrete high 
amounts of PGE2 in the inflammatory synovium [46]. 
 
The destructive potential of RASF is reflected by their ability to attach to certain cartilage 
components. Galectin-3 is triggered in RASF upon attachment to type VI collagen or cartilage 
oligomeric matrix protein (COMP) [47]. The adhesion to COMP occurs via the V3 integrin 
receptor. The adhesion to fibronectin rich cartilage areas is maintained by overexpression of 
beta integrin receptors (VLA-3, VLA-4, VLA-5) [48]. Furthermore, RASF express other 
adhesion molecules such as VCAM-1 and CS1 fibronectin isoform, which bind to lymphocyte 
integrin receptors and contribute to the maintenance of the inflammatory response [49]. 
Cadherin 11 is also expressed by RASF and in vitro facilitates the invasion of RASF into the 
cartilage [50].  
 
CD44, the hyaluronic acid receptor, and its isoforms are another group of molecules 
associated with the destructive potential of RASF. In this regard, it is interesting to note that 
anti-CD44 antibodies inhibit the RASF-mediated destruction of cartilage [51]. Possibly, 
certain CD44 isoforms (such as CD44v8-v9) are specific for the invasive behaviour of RASF 
[52]. 
 
The degradation of the extracellular matrix is caused by the action of matrix 
metalloproteinases (MMPs) [53]. It is known that RASFs secrete MMP-1, MMP-3 and MMP-
13 [54]. In addition, RASF produce MMP-14 and MMP-15 which belong to a family of 
membrane specific MMPs, called MT-MMPs, which activate MMP-2 and MMP-13 [55]. 
Another important group of extracellular matrix (ECM) degrading enzymes are cathepsins B, 
K and L [56]. These enzymes have been shown to be produced by RASF at sites of invasion 
and thought to contribute significantly to the joint damage. 
 
Bone destruction is mainly caused by osteoclasts. In the synovial fluid of RA patients, large 
amounts of RANKL have been detected. RANKL, together with GM-CSF, promotes the 
differentiation of osteoblasts and monocyte progenitor cells into osteoclasts [14]. Most 
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interesting, RASFs secrete RANKL at sites of invasion [57], suggesting a link between 
activation of SF and osteoclastogenesis.  
 
 
Figure 3: Characteristics of activated rheumatoid arthritis synovial fibroblast (RASF) 
[adapted from Karouzakis E. et al. Immunology Letters 2006; 106(1):8-13] 
 
Retroviral-related sequences have been speculated as the etiologic agents for RA [58]. LINE-
1 (L1) retrotransposons replicate genome repetitive elements that are similar to retroviruses, 
but lack the env gene [59]. The sequence of L1 retrotransposons contains two open reading 
frames. Open reading frame 2 (ORF2) encodes for a 150kd reverse transcriptase with 
endonuclease activity that is essential for retrotransposition. Open reading frame 1 (ORF1) 
transcribes for a 40 kd protein (p40). L1-p40 has been reported in the pathogenesis of cancer 
[60]. Neidhart et al described the expression of L1-p40 in synovial tissue, particularly at sites 
of joint destruction [61]. The L1-p40 protein normally acts as a cis-activator of the L1-p150 
protein, and in addition it has been hypothesized that it might act as a trans-activator, 
triggering the expression of genes involved in the activation of RASF. Thus, in L1-p40-
transfected RASF, p38 delta MAPK, c-met protooncogenes (the receptor for hepatocyte 
growth factor) and galectin-3 binding protein were upregulated [61, 62]. Interestingly, the 
expression of L1-p40 was localised at sites of invasion and is thought to play a major role in 
the upregulation of p38δ MAPK. The LINE-1 family of retrotransposons have a short internal 
promoter, the transcriptional activityof which is regulated by DNA methylation [62]. The 
increased activity of L1-p40 in RASF was associated with genomic hypomethylation [61, 62]. 
This was the first evidence of an epigenetic abnormality in the genome of RASF. 
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5. Epigenetics [adapted from Karouzakis E. et al. European Musculoskeletal Review 2008, 3: 
41-43, Karouzakis E. et al. Nature Reviews Rheumatology 2009; 5(5): 266-72, and 
Karouzakis E. et al. Advances in Experimental Medicine and Biology 2011, 711: 137-149] 
 
Epigenetics is an area of research that, in rheumatology, has only very recently been explored. 
It regards changes in gene expression that occur without a change in the DNA sequence. 
Epigenetics include DNA methylation and histone modifications (Figure 4). The interplay 
between these two processes controls the accessibility of chromatin to transcription factors. 
 
 
Figure 4: The two main components of the epigenetic code [63]: DNA methylation and 
histone modifications. 
 
 
DNA methylation involves the addition of a methyl group in the 5’ position of the cytosine 
base pair ring. It is the oldest epigenetic modification that is found in bacteria, fungi and 
plants. The organisms that do not methylate their own DNA are relatively small and include 
C.elegans and S.cerevisiae. DNA methylation plays important role in the developmental 
process. In embryonic development, DNA methylation during fertilisation of female and male 
genomes undergoes extensive demethylation [64]. New methylation marks are established by 
de novo methylation. Mice that have lost DNA methylation are embryonic lethal during organ 
development (Figure 5) [65]. Also, changes in DNA methylation are associated with 
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pathological conditions such as different types of cancer [66]. In humans, DNA methylation is 
found in the sequence context of 5`-CpG-3` [67]. Distinct patterns of DNA methylation are 
established during development. These patterns are stable and transmitted to next generations. 
Regulatory sequences such as promoters of housekeeping genes are kept methylation free. 
CpG islands are often associated with promoters of genes and have been thought as key 
factors in gene regulation. They are kept methylation free in somatic cells. However, different 
tumor suppressor genes have been shown to be silenced by promoter methylation of CpG 
islands [68]. The following criteria have been used to define a CpG island: G+C content of 
more than 55%, an observed vs. expected ratio of more than 0.65 and minimum size 500bp 
[69]. 
 
 
Figure 5: DNA methylation in development [70]. 
 
5.1 DNA methyltransferases [adapted from Jörg Tost Epigenetics book ref (84)] 
  
DNA methylation is an enzymatic reaction catalyzed by DNA methyltransferase 1 (DNMT1) 
[71] (Figures 6 and 7). DNMT1 is responsible for copying marks of methylation in the 
context of CpG dinucleotides during somatic cell replication. It targets hemimethylated DNA 
and catalyses the transfer of a methyl group from S-adenosylmethionine (SAM) to the 5’ 
prime end of the cytosine base pair [67]. The end product is 5-methylcytosine.  
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Figure 6: DNA methyltransferase catalyses the conversion of cytosine to 5-methylcytosine 
[72]. 
 
The full human DNMT1 cDNA was cloned and mapped in chromosome 19p13.2 [73]. It has 
80% homology with the mouse at the mRNA level and 74% homology at the amino acid 
level. DNMT1 protein has two domains: regulatory and catalytic [73]. The regulatory domain 
is located at the N’ terminal end of the protein and is responsible for all protein to protein 
interactions. It targets the protein in the replication fork through a proliferating cell nuclear 
antigen (PCNA) domain binding domain [74]. PCNA targets DNMT1 in the replication fork, 
but it does not affect its methylation activity. It also possesses a conserved cysteine rich CxxC 
region that interacts with histone deacetylases (HDAC1/2) and regulates transcriptional 
repression through chromatin modification [75]. DNMT1 is also associated with other 
proteins including retinoblastoma (Rb), p53, Sp1 and histone H3K9 methyltransferase 
SUV39H1 [76, 77]. The carboxylic terminal end of the protein contains the catalytic motifs 
IV and VI which are responsible for the enzymatic function of the protein. The motif IX for 
the ability of the DNMT1 to interact with DNA double helix and the I, X motif are associated 
with the binding of S-adenosylmethionine (SAM), the cell methyl’s donor. DNMT1 is 
ubiquitously expressed with the highest expression levels in the brain, lung, heart and 
placenta. The expression of the protein increases during the S phase of the cell cycle. 
Proliferative cells express high levels of DNMT1 in order to maintain DNA methylation 
during replication [78]. The presence of DNMT1 is essential for normal embryonic 
development. DNMT1 knock out caused embryonic lethality in mouse embryos [79]. DNA 
demethylation in cell lines has been achieved in vitro by DNMT1 RNA interference and 
treatment with the chemotherapeutic agent 5-azacytidine which inhibits its enzymatic activity. 
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During embryonic development the DNA methyltransferases 3a and 3b (DNMT3A/B) are 
expressed and add the initially methylated CpG dinucleotides in the DNA. (Figure 7) The 
mouse and human sequences of DNMT3A/3B have 94%/98% homology [80]. They share a 
conserved catalytic domain with the other metyltransferases DNMT1 and DNMT2. In 
contrast to DNMT1 that requires the intramolecular interaction of N and C terminal domain, 
the DNMT3A/B requires only the catalytic subunit [81]. They are very important for the 
establishment of imprinted genes during embryonic development. Similar to DNMT1, these 
enzymes interact with different proteins that regulate DNA damage and histone modifications. 
In addition, the interaction of DNMT1 and another methyltransferase DNMT3L might 
enhance both of their activity [82]. 
 
DNMT2 is another member of the family that has a conserved catalytic methyltransferase 
motif but it does not methylate DNA in vivo[83]. This was shown in knock out embryonic 
stem cells that retain DNA methylation of their genome. In contrast to the nuclear localisation 
of the other methyltransferases, DNMT2A is located in the cytoplasm. It functions as a RNA 
methyltransferase that specifically methylates tRNAasp [83]. The function of this modification 
to date remains unknown.  
 
Figure 7: DNA methyltransferase family [84]. 
 
Defects in DNA methyltransferases have been implicated in tumorigenesis and developmental 
disorders. In cancer, epigenetic changes have been observed in a variety of tumors and 
include global hypomethylation and specific hypermethylation of tumor suppressor genes 
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promoters. Analysis of the expression of DNMT1 and DNMT3A showed an increased level in 
tumors compared to normal tissues [85]. Mutations of DNMT1 have been identified in 
colorectal cancer. Loss of p53 which regulates DNMT1 transcriptionally can cause 
abnormalities in DNA methylation [86]. Increase of DNMT1 does not always correlate with 
genomic hypermethylation. Progression of hepatocellular carcinoma (HCC) is followed by 
genomic hypomethylation and increased expression of DNMT1 [87]. However, in general, the 
increase of DNMT1 is associated with increased proliferation of tumor cells. 
 
Immunodeficiency centromere instability and facial anomalies (ICF) syndrome is an 
autosomal recessive disease associated with abnormal DNA methylation and mutations in the 
catalytic domain of DNMT3B [88]. The disease causes immunodeficiency and involves 
hypomethylation of repetitive sequences and chromosomal instability due to hypomethylation 
of satellite repeats and the expression of genes on the X inactive chromosome. The 
immunodeficiency is caused by the reduction in immunoglobulin production. 
 
5.2 Functional role of DNA methylation [adapted from Jörg Tost Epigenetics book ref (84)] 
 
5.2.1 Transcriptional repression 
 
DNA methylation represses the transcriptional regulation of genes. This mechanism is 
particularly important in embryogenesis and cell differentiation. Three mechanisms have been 
proposed (Figure 8). 
 
A first mechanism is the inhibition of transcription factor binding to promoter sites with 
methylated CpGs. Several transcription factors such as AP1, NFkβ, cAMP response element 
binding (CREB), E2F recognise sequences that contain CpG islands or sequences with 
accumulated CGs and the methylation of such sites inhibits the binding of specific 
transcription factors [89].   
 
A second mechanism is mediated by the direct binding of transcription repressors that 
recognise the methylated CpG motifs and inhibit binding of transcription factors and DNA 
polymerase II.   
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The third mechanism is associated with proteins that bind methylated DNA (such as MBD1, 
MeCP2, MBD3) blocking the interaction of promoters with transcription factors and DNA 
polymerase II. They also interact with histone deacetylases to change the chromatin structure 
[90]. 
 
 
 
Figure 8: Mechanisms of transcriptional repression mediated by cytosine methylation: a) 
Active transcription. b) Repression by inhibiting transcription factors. c) Repression by 
MeCP2.        5-methylcytosine 
 
MeCP2, as DNMTs, is important for embryonic development and binds to methylated CpGs 
with A/T-rich runs. It has two regulatory domains: a methyl CpG binding domain that targets 
the protein to methylated DNA and a transcriptional repressor domain (TSD) that can inhibit 
transcription via the recruitment of histone deacetylases including mSIN3a, HDAC1 and 
HDAC2 [91]. 
 
MBD1, MBD2, MBD3 induced also repressed gene transcription through their interaction 
with proteins involved in chromatin remodelling [90]. In particular, MBD2 has been found to 
be associated with the NuRD/Mi-2 histone deacetylase complex and all together to form the 
MeCP1 complex. MBD3 is an internal component of the NuRD complex [92]. 
 
MBD4 is a DNA repair protein that repairs C→T transitions at CpG sites due to deamination 
of 5-methylcytosine  and recognises methylated CpGs along with G/T mismatches [93]. 
Interestingly, many C→T transitions at CpG sites occurred at the MBD4 knockout mice. 
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In addition of repressing gene transcription, DNA methylation is associated with the 
inactivation of repetitive sequences, of X chromosome and genomic imprinting.  
 
5.2.2 Repetitive sequences [adapted from Jörg Tost Epigenetics book ref (84)] 
 
Repetitive sequences comprise a group of transposable elements or simple repeat sequences 
such as DNA satellites. The major human DNA satellites are the centromeric Sata, Sat2 and 
Sat3. Hypomethylation of these satellite repeats have been shown in the ICF syndrome as 
mentioned above. Transposable elements are DNA sequences that have the ability to integrate 
randomly into the human genome. Three types of transposable elements exist in the human 
genome: DNA transposons, the retrotransposons and endogenous retroviruses. DNA 
transposons are small elements that have a single transposase enzyme which is not functional 
due to a frameshift mutation. However, some remain active and favor the genomic instability. 
Retrotransposons are classified into those with a long terminal repeat in their sequence called 
LTR retrotransposons and those without called non-LTR retrotransposons [94]. These 
elements can move and integrate into other parts of human genome. When migrating into the 
promoters of the gene, they can modify gene transcription. LINE-1 elements, which are 
normally silenced by DNA methylation, belong to the group of non LTR retrotransposons. 
Their full length is 4-6kb and cover 21% of the human genome. Another group of transposons 
that depend on LINE-1 for transposition is the SINE family. The Alu repeats are also a 
member of this family. They are short in length (100-300bp) and cover 11% of the human 
genome.   
 
5.2.3 X inactivation 
 
X inactivation involves silencing of genes in one of two X chromosomes in females. The 
inactivation process involves the expression of untranslated transcripts such as Xist, which 
causes the heterochromatinization of X chromosome. The inactive state of the X chromosome 
depends on DNA methylation [95]. Different CpG sites along the chromosome are methylated 
and keep the silent state of gene expression in the X chromosome. 
 
Imprinted genes are inactivated in one allele in a specific parental way. The regulatory 
elements of imprinted genes contain CpG islands that are methylated depending on the 
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parental origin. These regions are called imprinted control regions (ICR). The initiation of 
imprinting is performed during gametogenesis by DNMT3A/B. At this stage, DNA 
methylation marks are imprinted in a germ line specific manner. After fertilisation, the new 
imprinted code is propagated during development in somatic cells. An example of an 
imprinted locus, it is the insulin growth factor 2 (IGF2)/H19 locus [96]. These two genes are 
separated 70 bp and have the same transcriptional orientation. A specific ICR region is 
located between these two genes which regulate the expression of genes in a parental 
depending way.  
 
5.3 Histone modifications 
 
Another mechanism imprinted on the chromatin is the modification of histones (by 
acetylation, methylation, phosphorylation and ubiquitination) [97]. There are two classes of 
histones conserved in humans: the core histones H2A, H2B, H3, and H4 and the linker 
histones H1 and H5. Two of each of the core histones forme an octamer structure called the 
nucleosome. The DNA is wrapped around the nucleosome and forms a stable molecular 
structure. Post-translational modifications of the histone tails regulate the accessibility of 
transcription factors. These modifications, mainly located on lysine and arginine residues, are 
called “marks” and together determine the histone code. Histone acetylation and methylation 
are catalysed by the enzymes histone acetyltransferases and histone methyltransferases[98]. 
Molecular analysis of these marks showed that acetylation of H3/H4 lysines is associated with 
transcriptional activation, whereas methylation of H3 lysine 9 is associated with gene 
inactivation [98]. Hypoacetylation of H3 and H4 has been found in CD4 T cells from SLE 
patients and splenocytes from MRL/lpr lupus mice [99, 100]. Histones are also affected by 
citrullination. PADI4 is the enzyme that converts the methylated arginine to into citrulline. 
RA patients have autoantibodies against citrullinated antigen [101]. Whether or not histone 
citrullination is significant in the generation of autoantibodies, should be the subject of future 
investigation.  
 
Histone deacetylases (HDACs) are the enzymes that remove the acetyl mark from the histone 
tails. Then, the chromatin changes conformation and the binding of transcription factors are 
inhibited. These enzymes interact with the DNA methylation proteins and together regulate 
gene transcription in somatic cells. HDACs have been reported to be deregulated in cancers as 
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well as in autoimmune diseases [102]. The first published report that the HDAC activity was 
found to be decreased in RASF synovium, suggested that inhibiton of HDACs is not 
necessary [103]. However, in several animal models of arthritis, HDACs inhibitors showed 
beneficial effects [104, 105].  
 
6. Investigating DNA methylation in rheumatoid arthritis [adapted from Karouzakis E. et 
al. European Musculoskeletal Review 2008, 3: 41-43] 
 
The area of research that studies epigenetic modifications regulating gene expression using 
different techniques is called epigenomics. Global changes of DNA methylation were studied 
in our group using two different methods. Immunohistochemistry is a useful technique to 
detect the expression of different proteins in patient biopsies. We used a modified 
immunohistochemistry protocol and mouse monoclonal antibodies directed against 5-
methylcytosine to detect changes in DNA methylation between healthy individuals and 
patients with rheumatoid arthritis [106]. The same antibodies can also be used for 
fluorescence staining of cell nuclei. Fluorescence activated cell sorting (FACS) analysis can 
quantify the amount of 5-methylcytosine in the nuclei (Figure 9A). Another accurate 
quantification of 5-methylcytosine is high-performance liquid chromatography (HPLC) [107]. 
Here, the DNA is digested into single nucleotides and quantified by HPLC.  
 
More specific approaches are used to identify gene targets that have been differentially 
methylated (Figure 9A). The bisulfite sequencing method can detect and quantify changes in 
CpG sites of gene promoters [108]. The assay is based on the bisulfite conversion of 
unmethylated cytosine to uracil, whereas 5-methylcytosine remains unchanged. After bisulfite 
treatment both unmodified and modified samples are amplified by PCR using specific 
bisulfite primers that are specific for a given gene locus. During PCR, uracils are converted 
into thymidines. Then, the PCR products are cloned into a plasmid vector and sequenced. 
Unchanged cytosine in the DNA sequence indicates the presence of a methylated cytosine, 
whereas a conversion from cytosine to thymidine indicates an unmethylated cytosine. 
 
In combination with the above method, the addition of the pharmaceutical demethylating 
agent 5-azacytidine (5-azaC) can detect genes regulated by DNA methylation followed by 
RT-PCR or human genomic expression arrays (Figure 9B).  
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Figure 9:  Methods to study DNA methylation changes in tissues and cell cultures. A) Global 
and specific analysis of DNA methylation marks. B) DNA hypomethylation and screening by 
complementary (cDNA) microarrays [adapted from Karouzakis E. et al. European 
Musculoskeletal Review 2008, 3: 41-43]. 
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7. Objective 
 
The major focus of the thesis is to understand the “spontaneous” activated phenotype of 
synovial fibroblasts from RA patients. To date, there are no genetic markers available to 
explain the invasive ability of RA synovial fibroblasts. Therefore, epigenetic analysis of 
RASF might provide important clues into the RASF activated phenotype. DNA methylation is 
an important modification that can lead to cellular transformation and differentiation. The 
aims of the current study are the following: 
 To study global methylation in RA synovium and compare it with the OA synovium. 
 To analyse the global methylation in RASF cell cultures and compare it with OASF 
cell cultures. 
 To study the effect of pro-inflammatory cytokines on global methylation. 
 To measure the expression of DNMTs in the synovium and cell cultures in order to 
find an explanation for the global DNA hypomethylation. 
 To search for changes in gene and protein expression after genomic hypomethylation, 
with the hypothesis that demethylated fibroblasts from healthy individuals will acquire 
an activated RASF-like phenotype.  
 To identify specific genes which are influenced by DNA hypomethylation and are 
important in the pathogenesis, and thereby describing new epigenetic markers in RA. 
 
The information will improve our understanding of the activated phenotype of RASF and 
possibly provide new therapeutic strategies to reverse the destructive behaviour of those cells. 
In this study, we compared two groups of patients, suffering either from rheumatoid arthritis 
or osteoarthritis. The osteoarthritis synovial tissues and cell cultures were regarded as normal 
control cells, since they had no destructive properties. In chapter 2, we measured the global 
methylation in RA and OA synovial tissues, as well as in corresponding cultured synovial 
fibroblasts. For the demethylation and microarray analysis, we used a culture of normal 
synovial fibroblast obtained from the biopsy of a trauma patient. We investigated the possible 
result of DNA hypomethylation on those normal fibroblasts and performed cDNA microarray 
studies to analyse the changes in gene expression. Indeed, these cells acquired many 
characteristics of RASFs, including increased expression of cytokine receptors, adhesion 
molecules and matrix-degrading enzymes. Finally, in chapter 3, we analysed the promoter 
methylation of the chemokine CXCL12, which has been repeatedly found to be a 
differentially expressed gene between normal / osteoarthritis and RA synovial tissues. 
                                                                                                                     
Chapter 1                                                                                                                Introduction 
 
 
31
Accordingly, its transcription and protein expression were upregulated in cultures of RASF in 
vitro. We hypothesized that the level of CXCL12 transcription is regulated by the methylation 
of its promoter. Indeed, we reported here CXCL12 as an epigenetic marker in RA. 
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1. Abstract 
 
Rheumatoid arthritis synovial fibroblasts (RASF) are phenotypically activated and aggressive. 
We undertook this study to investigate whether the intrinsic activation of RASF is due to 
global genomic hypomethylation, an epigenetic modification.   
 
Global genomic hypomethylation was assessed by immunohistochemistry, flow cytometry 
and LINE-1 promoter bisulfite sequencing. The levels of DNA-methyltransferase 1 (DNMT1) 
were determined in synovial tissues and cultured synovial fibroblasts by Western blotting, 
before and after treatment with cytokines and growth factors. Normal synovial fibroblasts 
(NSF) were treated for 3 months with a nontoxic dose of the DNA hypomethylation drug 5-
azacytidine (5-azaC) and changes in gene expression were revealed using cDNA arrays. The 
phenotypic changes were confirmed by flow cytometry.   
 
In situ and in vitro, RASF DNA had fewer 5-methylcytosine and methylated CG sites 
upstream of an LINE-1 open reading frame than did DNA of osteoarthritis synovial 
fibroblasts, and proliferating RASF were deficient in DNMT1. Using 5-azaC, we reproduced 
the activated phenotype of RASF in NSF. One hundred eighty six genes were upregulated 
more than two-fold by hypomethylation, with enhanced protein expression. These included 
growth factors and receptors, extracellular matrix proteins, adhesion molecules, and matrix-
degrading enzymes. The hypomethylating milieu induced irreversible phenotypic changes in 
NSF, which resembled those of the activated phenotype of RASF.  
 
DNA hypomethylation contributes to the chronicity of rheumatoid arthritis and could be 
responsible for the limitation of current therapies. 
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2. Introduction 
 
Rheumatoid arthritis (RA), which affects approximately 1% of the population, is a chronic 
autoimmune disease involving progressive destruction of the affected joints. Pro-
inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF) are involved in its pathogenesis [1-3]. Anti-TNF therapies in 
particular have been shown to provide substantial benefit to patients not only through the 
reduction of signs and symptoms of the disease, but also by the inhibition of joint destruction 
[1]. However, treatments with current biologics, including anti-TNF, anti-T cells and anti-B 
cells therapies, are only successful in at best in 60% of the treated patients and are still unable 
to cure the disease. A cytokine-independent pathway appears responsible for the ongoing joint 
destruction mediated by synovial fibroblasts (SF) [2]. Since implantation of rheumatoid 
arthritis SF (RASF) with human cartilage into SCID mice causes invasion into the cartilage 
without the support of the cells of the human immune system, it has been proposed that the 
activated phenotype is an “intrinsic” property of these cells [3].  
 
SF, more than other types of fibroblasts, acquire phenotypic characteristics commonly 
associated with transformed cells [4]. RASF show “spontaneous” activities, associated with 
aggressive behavior and they differ from the SF of patients with osteoarthritis (OASF) or 
normal SF (NSF). For example, RASF up-regulate proto-oncogenes [5], specific matrix 
degrading enzymes [6], adhesion molecules [7], and cytokines [8]. These observations of an 
intrinsically activated cellular phenotype prompted us to search for epigenetic modifications.  
 
In somatic cells, DNMT1 is the predominant DNA methyltransferase [9, 10]. Reduction of 
DNMT1 levels leads to hypomethylation, genomic instability, and tumorigenesis. Direct 
interaction between DNMT1 and proliferating cell nuclear antigen (PCNA) ensures that 
patterns of methylation are faithfully preserved in DNA synthesis [10]. Moreover, repetitive 
sequences such as LINE-1, Alu, and satellite alpha repeats are silenced by methylation in 
normal cells, and can be used as markers of global hypomethylation [11]. Our group and 
others [12, 13] reported a reactivation of the endogenous retroviral element LINE-1 in the RA 
synovial lining, and at sites of invasion. These reports suggest that global genomic 
hypomethylation plays a role in the pathogenesis of RA, and that genes normally silenced by 
methylation might contribute to the activated phenotype of RASF [12].  
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Here we show that DNA demethylation of normal synovial fibroblasts (NSF) induces a 
cellular phenotype resembling that of activated RASF. Genomic hypomethylation is a 
characteristic of RASF and is involved in the pathogenesis of RA.  
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3. Material and Methods 
 
3.1 Cell cultures: RASF and OASF were isolated from synovial tissues obtained during joint 
replacement surgery. Normal SF were isolated from a small joint biopsy of a trauma patient. 
The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) including 10% 
fetal calf serum (FCS) and used between passages 5 and 6 (reagents were from Life 
Technologies, Basel, Switzerland). The procedure was approved by the Ethics Committee of 
the University Hospital, Zurich, Switzerland). The characteristics of the study patients were 
shown in Table 1. 
 
 
Table 1. Characteristics of the study patients. RA= rheumatoid arthritis; OA = osteoarthritis; 
NSAIDs = non-steroidal anti-inflammatory drugs; DMARDs = disease-modifying 
antirheumatic drugs; anti-TNF = anti-tumor necrosis factor;  NA= not assessed; CRP = C-
reactive protein. * Rheumatoid factor (RF) positivity was defined as > 20 IU/ml. 
 
3.2 Immunohistochemistry for 5-methylcytosine: Formalin fixed, paraffin-embedded 
sections of synovial tissues were deparaffinised and treated at 80°C for 30 minutes with 
citrate buffer (pH 3.4). The tissue slides were incubated with 2N HCL for 2 hours at 37 C. 
After acid treatment, the slides were washed well with Phosphate Buffer Saline (PBS) / 0.05% 
Tween-20 (PBST). To determine the methylation in the synovial tissues, mouse monoclonal 
antibodies against 5-methylcytosine (5-MeC) (Imgenex, San Diego, CA, USA) were used. 
Mouse IgG isotype (Dako, Glostrup, Denmark) served as negative controls. Double staining 
with vimentin (using murine anti-human monoclonal antibodies, clone V9, Dako) was used to 
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stain synovial fibroblasts. The antibodies were incubated overnight at 4°C. Bound antibodies 
were detected by incubation with biotinylated goat anti-mouse IgG (Jackon Lab., Bar Arbor, 
Maine, USA) for 1 hour. The slides were incubated with ABC reagents for HRP (Vectastain, 
Vector Lab., Burlingame, CA, USA).The methylcytosine modification and vimentin were 
visualised using 3.3-diaminobenzidine (Vector) and HistoGreen (Histoprime, Linaris, 
Wertheim-Bettingen, Germany) respectively. ImageJ software (National Institute of Health) 
was used to analyse the mean intensity of nuclei in the patient tissues. We acquired three 
different microscopic field images per patient tissue sample. The color images were converted 
into 8 bit gray/white images. The threshold was adjusted for each image in order to specify 
only the nuclei. The means of gray/white intensity of all nuclei in the image were obtained 
and compared. The numerical values given by software were converted to a mean intensity 
unit using the equation: Mean intensity = (1/mean of gray intensity /white intensity) x 100. 
 
3.3 Flow cytometry for 5-MeC: The cells were fixed with 0.25% paraformaldehyde for 10 
minutes at 37°C and kept on ice for 10 minutes before addition of 88% methanol / 12% PBS 
for 10 minutes at -20°C. The nuclei were washed twice with PBST-BSA and treated with 1N 
HCl for 40 minutes at 37°C. Neutralization of the acidic solution was performed by one wash 
step with 0.1 M borate buffer pH 8.5 and two wash steps with PBST/BSA. The nuclei were 
incubated for 20 minutes at 37°C with a blocking solution that contains PBST/BSA 
supplemented with 10 % FCS. The nuclei were incubated with anti-5-MeC antibodies 
(Imgenex) for 1 hour at 37°C, washed twice with PBS and incubated with anti-mouse FITC 
antibodies for 30 minutes at 37°C (BD Biosciences, Heidelberg, Germany). Finally, the 
samples were stained also with propidium iodine (PI) before being analysed using FACS 
(FACScalibur, BD Biosciences).  
 
3.4 Bisulfite sequencing for LINE-1 promoter: Genomic DNA was prepared from RASF 
and OASF using the QiAmp DNA blood Mini kit (Qiagen, Hombrechtikon, Switzerland). The 
DNA (1µg) was bisulfite modified using the EpiTect bisulfite kit (Qiagen). The modified 
DNA was eluted in 20 l of Tris Buffer (pH 8,5) and stored at -20°C. PCR amplification of 
bisulfite modified DNA (2 µl) was performed using Hot Start PCR and the AmpliTaq Gold 
polymerase (Applied Biosystems, Rotkreuz, Switzerland). Primers were designed for the CpG 
area upstream of LINE-1 promoter (X58075, -420 to -49 bp) forward 5-TTT ATT AGG GAG 
TGT TAG ATA GTG GG-3 and reverse 5-AAA CCC TCT AAA CCA AAT ATA AAA 
TAT AAT-3. The online MethPrimer software was used 
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(http://www.urogene.org/methprimer/). The PCR purified fragment was cloned using the 
TOPO TA cloning kit according to manufacturer instructions (Invitrogen, Carlsbad, CA, 
USA). The positive clones were sequenced (Microsynth, Balgach, Switzerland). The data 
analysis was performed using the BiQ analyzer software (Max Plank Institut, Munich, 
Germany). 
 
3.5 Immunohistochemistry for LINE-1 proteins: LINE-1 ORF1p and ORF2p were 
detected by immunohistochemistry on paraffin-embedded sections of synovial tissues. Rabbit 
polyclonal antibodies against LINE-1 ORF1p and chicken polyclonal antibodies against 
LINE-1 ORF2p (obtained from G.G. Schumann, Paul-Ehrlich-Institut, Section PR2 / 
Retroelements, Langen, Germany), anti-rabbit or anti-chicken biotinylated antibodies, 
streptavidin conjugated to alkaline phosphatase (Jackson Lab.) were used and Fast Red 
Substrate (Vector Lab.) revealed the staining. Non-immune rabbit or chicken sera were used 
as a control for primary antibodies. 
 
3.6 Western blotting for DNMT1 and PCNA: Tissue or cells were prepared by lyses in 
RIPA buffer (50 mM Tris HCL pH 8, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 
0.1% SDS, reagents from Sigma-Aldrich, Buchs, Switzerland). Proteins were separated in 
10% SDS-polycrylamide gel and transferred to nitrocellulose membranes. Membranes were 
blocked for 1 hour in 5% nonfat dry milk with 0.05% Tween-20 in TBS (pH 7.4) and were 
incubated overnight with antibodies against human DNMT1 (Abcam, Cambridge, United 
Kingdom) or PCNA (PC10, Imgenex). After incubation with goat HRP-conjugated anti-
mouse IgG secondary antibodies (Jackson Lab.) in 5 % non-fat dry milk with 0.05% Tween-
20 in TBS (pH 7.4), bound antibodies were visualised using ECL chemiluminescence 
(Amersham, Buckinghamshire, United Kingdom). Intensity of the bands were evaluated by 
densitometry (Alphaimager 2200, Witec AG, Littau, Switzerland).  
 
3.7 Treatment with TNFIL-1 or platelet derived growth factor (PDGF): RASF and 
OASF were passaged 48 hours and serum-starved (0,5% FCS) 24 hours before adding 10 
ng/ml recombinant human TNF, 1 ng/ml IL-1 or 10 ng/ml PDGF (R&D Systems, 
Minneapolis, MN, USA) (or medium alone) to the cell culture. The cells were kept in DMEM 
containing 10% FCS and collected after 24 or 48 hours. 
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3.8 Microarray of 5-Azacytidine induced gene expression: NSF (n=1) were treated with a 
low dose of 5-azacytidine (0,1 M/ml 5-azaC for 3 months, with medium changed every 3 
days over 2 passages)  (Sigma-Aldrich) or left untreated (control group). The long incubation 
was used to have enough cell divisions and to mimic the chronic state of the disease. Total 
RNA was isolated with the RNeasy MiniPrep Kit (Qiagen) including treatment with RNase-
free DNase. Double-stranded cDNA was synthesized from 5µg total RNA using the 
GeneChip One-cycle cDNA Synthesis Kit, including labeling with the One-cycle Target 
Labeling Assay (Invitrogen). The labeled cDNA was hybridized with the probe sets present 
on the Human Genome U133 Plus 2.0 Gene Expression Array (Affymetrix, Santa Clara, CA), 
using the Fluidics Station 450, according to standard protocols. The hybridization-picture was 
scanned with a GeneChip Scanner 3000 and further analyzed using the GCOS software. 
Data were normalized (measurements less than 0.01 were set to 0.01, and normalization per 
chip was set to 50th percentile) and analyzed with GeneSpring Microarray Analysis Software 
(Silicon Genetics, Redwood City, CA). Filters were set on 2-fold regulation, expression levels 
had to be >2.0, flags had to be present or marginal in at least one out of 2 compared samples. 
 
3.9 FACS for phenotyping of RASF: RASF and OASF were treated with a low dose of 5-
azaC (0,1 M/ml 5-azaC for 2 weeks, with medium changed each 3 days). The cells were 
detached using Accutase (Omnilab) and incubated with the following primary antibodies or 
isotype controls for 1 hour at 4°C in DMEM including 10% FCS:anti-CD10,anti-CD26, anti-
CD29, anti-CD36, anti-CD46, anti-CD130 (murine monoclonal antibodies, BD Pharmingen), 
anti- Matrix metalloproteinase 14 (MMP-14) hinge region (rabbit polyclonal antibodies, 
Chemicon, Zug, Switzerland), transforming growth factor  receptor 2 (TGF-R2), CK 
(murine polyclonal antibodies, Abnova, Heidelberg, Germany). Cathepsin K (CK) was 
measured in permeabilized cells (using DakoCytomation IntraStain). The cells were further 
incubated with fluorescein-conjugated secondary antibodies: goat anti-mouse IgG/IgM or rat 
anti-rabbit IgG (BD Pharmingen). The mean fluorescence intensity was determined by a 
FACScalibur.  
 
3.10 Gene analysis: The following online programs were used: Ensembl genome browser 
(http://www.ensembl.org/index.html), CpGplot (http://www.ebi.ac.uk/emboss/cpgplot/), 
Transcription Element Search System (http://www.cbil.upenn.edu/cgi-bin/tess/tess) and TFBS 
list (http://lgsun.grc.nia.nih.gov/geneindex/mm6/TFBS/list.html). 
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3.11 Statistical analysis. Differences between patient groups were evaluated using the Mann-
Witney U-test, whereas changes in the same cell culture were evaluated using the Wilcoxon 
signed ranks test. Analysis of frequency was performed using chi squared tests.  
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4. Results 
 
4.1 Global genomic hypomethylation in RA synovial tissues. To visualize global genomic 
methylation, paraffin-embedded synovial tissue sections from RA and OA patients were 
stained with anti-5-MeC monoclonal antibodies (Fig. 1). In RA, the vimentin positive 
synovial fibroblasts showed decreased stainings of cell nuclei in both the lining and the 
sublining, reflecting a generalized genomic hypomethylation (Fig.1A). Detailed image 
analysis of OA and RA nuclei in the synovial lining and sublining showed that RA nuclei 
were stained less densely in comparison to OA nuclei (Fig.1B). Thus, synovial cell nuclei 
were significantly less methylated in RA, than in OA (Fig.1C, n = 6 each, p < 0.05).  
 
 
Figure 1. Immunohistochemistry shows global genomic hypomethylation in rheumatoid 
arthritis (RA) synovial tissue.  
A) Osteoarthritis (OA) and RA synovial tissue was stained with monoclonal antibodies 
against 5-methylcytosine (brown) and vimentin (green). B) RA synovial fibroblasts showed 
lower intensity of brown staining (5-methylcytosine; arrows), than the OA synovial 
fibroblasts. Representative intensity histograms obtained with ImageJ software (NIH Image, 
National Institutes of Health, Bethesda, MD; online at: http://rsbweb.nih.gov/ij/).C, RA 
synovial tissue was significantly less methylated than the OA synovial tissues, as reflected by 
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the lower nuclear staining of 5-methylcytosine (n = 6 samples each, determined by  ImageJ 
software analysis). Horizontal bars indicate the mean. (Original magnification x 200 in A and 
B) 
 
4.2 Global genomic hypomethylation in RASF and effects of cytokines and growth 
factors.  
 
To determine whether RASF are still hypomethylated in vitro, SF were isolated from tissues 
and cultured for five to six passages. In addition, we investigated the effect on DNA 
methylation of exposure to physiological concentrations of pro-inflammatory cytokines and 
growth factors. Cells were stimulated or left untreated, and harvested. Cell nuclei were stained 
with anti-5-MeC monoclonal antibodies (Fig. 2A) and propidium iodide (Fig. 2B) and 
analyzed by flow cytometry. The cell nuclei of untreated RASF, compared with those of 
untreated OASF, showed significantly less 5-MeC staining (Fig. 2A/C, n = 6, p<0.05). In 
RASF, 5-MeC remained significantly reduced even in the presence of pro-inflammatory 
cytokines, TNF or IL-1 (n = 6, p<0.05). 
 
4.2.1 Cell cycle analysis.  
 
We determined the percentage of OASF and RASF cells in the G2/M phase in the different 
conditions, i.e. with or without the addition of cytokines or growth factors (Figs. 2B/D). The 
strongest increase occurred with TNF within 24 hours. However, no significant difference 
was detected between OASF and RASF in the different conditions (n = 6 each, p=0.8-0.9).  
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Figure 2. Flow cytometric analysis of cell nuclei confirms genomic hypomethylation of 
rheumatoid arthritis synovial fibroblasts (RASFs) in vitro; – effects of pro-inflammatory 
cytokines and growth factors. A) Nuclei of rheumatoid arthritis and osteoarthritis synovial 
fibroblasts (RASF and OASF) labeled with anti-5-methylcytosine (5-MeC)-FITC antibodies 
and evaluated by flow cytometry. Representative example of reduced 5-MeC in the nuclei of 
RASF (black), compared with OASF (white) (gray lines, IC: isotype control).  
B) Example of cell cycle analysis using propidium iodine (PI) showing distinct G1, S and 
G2/M phases, in unstimulated synovial fibroblasts or upon exposure for 24h  to TNFa.  
C) Histograms of mean fluorescence intensity (MFI) of stainings with 5-MeC. Unstimulated 
RASF showed a significant reduction in 5-MeC. The cells were treated with TNFa, IL-1β or 
PDGF. In all conditions tested – except PDGF -, the relative deficiency of 5-MeC remains 
significant in RASF, when compared to OASF (p<0.05, n = 6 each). 
D) Percentage of total cells in G2/M phase of the cell cycle in unstimulated and stimulated 
synovial fibroblasts (same experiment as in C). As expected, the proliferation increased upon 
stimulation, but no difference could be detected between OASFs and RASFs. NS = not 
significant. Values in C and D are the mean and SD.  
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4.3 Expression of DNMT1 and PCNA and effects of cytokines and growth factors.  
We performed Western bloting with specific monoclonal antibodies to search for a defect in 
the methylation pathway. Tissue and cell lysates were analyzed for the expression of DNMT1 
and PCNA. In RA synovial tissues, compared with OA synovial tissues, the ratio 
DNMT1/PCNA was significantly lower (n = 6 each, p < 0.05) (Fig. 3A). In RA, an increased 
rate of cell proliferation was associated with high levels of PCNA. In proliferating cells, it 
would be expected to find an increased expression of DNMT1; this was not the case in RA 
synovial tissues. The levels of DNMT1 were even lower in RA synovial tissue than in OA 
synovial tissue which showed low expression of PCNA and a low rate of proliferation. This 
observation suggested a deficient production or a decreased half-life of DNMT1 in the RA 
synovial tissue.  
In vitro, the DNMT1/PCNA ratio remained significantly lower in RASF, than in OASF (n = 
6, p<0.05) (Fig. 3B). We tested the effect of pro-inflammatory cytokines and growth factors 
on the expression of DNMT1 (Fig. 3C). Most importantly, in RASF, under all conditions 
tested, the DNMT1/PCNA ratio remained significantly lower, in comparison to OASF. 
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Figure 3. Relative deficiency of  DNMT1 in proliferating cells. 
 
A) The level of DNMT1 is very low in RA synovial tissue compared to OA synovial tissue, 
inspite of an increased expression of proliferating cell nuclear antigen (PCNA). Western blots 
show representative examples of DNMT1 and PCNA expression in synovial tissue from 2 OA 
patients and 2 RA patients. The PCNA/DNMT1 ratio was significantly reduced in RA (n=5 
samples each).  
B) The expression of DNMT1 was decreased also in RA synovial fibroblasts (RASF) in vitro, 
compared to OA synovial fibroblasts (OASF) (left, representative examples). The histogram 
shows that the ratio of DNMT1/PCNA is significantly lower in RASF, than in OASF. (n = 6 
samples each) 
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C) Representative Western blots show that stimulation of cells with TNFa for 24 hours 
increased the expression of PCNA, but the levels of DNMT1 in RASF remained very low. 
Importantly in all conditions tested (including those with IL-1b and PDGF), the 
DNMT1/PCNA ratio remained significantly reduced in RASF (n = 6 samples each). Values 
are the mean and SD. 
4.4 Hypomethylated LINE-1 promoter in RASF.  
Because LINE-1 proteins are expressed in the RA synovial tissues (Fig. 4A), we thought to 
determine whether their expression is due to genomic hypomethylation. 18 CG sites of the 
LINE-1 promoter / 5’-UTR (i.e., GenBank-Nr. X58075, 372bp between nucleotides -49 and -
420) were analyzed for changes in methylation by bisulfite sequencing. Genomic DNA 
derived from RASF revealed significantly fewer methylated CG sites upstream of the LINE-1 
ORF1, in comparison with OASF (78 + 2% versus 85 + 3% CG methylation, p < 0.05, n = 7 
patients, and 20 clones analyzed for each diagnosis) (Fig. 4B). Furthermore, we found that the 
methylation of L1 promoter in the isolated synovial fibroblasts correlated significantly with 
the expression of L1 ORF1p protein in the corresponding synovial tissue (Figure 4C). 
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Figure 4. LINE-1 proteins and promoter hypomethylation in  RASF. 
 
A) LINE-1 proteins (L1 ORF1p / p40 in fibroblasts at sites of cartilage destruction and L1 
ORF2p / p150 in round-shaped cells at sites of bone destruction) are expressed in rheumatoid 
arthritis (RA) synovial tissues (original magnification x 400). 
B) The LINE-1 promoter (5’-UTR, 372bp containing 18 CpG sites) is hypomethylated in 
RASF (black bars), compared with OASF (white bars). Bisulfite sequencing was performed in 
25 clones from seven RASF and seven OASF cultures. The results were analyzed using BiQ-
Analyser software and expressed in terms of mean plus standard deviation. CpG sites, 
particularly at positions one and nine, are significantly hypomethylated, in addition to a 
significant overall hypomethylation. The p values refer to differences between OASF and 
RASF (Mann-Whitney U-test). C) Correlation of LINE-1 promoter methylation in isolated 
synovial fibroblasts and L1 ORF1p protein expression in corresponding RA and OA synovial 
tissues. SF derived from RA tissue has a higher percentage of unmethylated and missing CpG 
than SF derived from OA tissue. The table shows the percentage of unmethylated CpG among 
the 18 CpG and the percentage of CpG which are missing from the patient genomic sequence 
versus the GenBank LINE-1 promoter sequence (Missing CpG). The total includes both 
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unmethylated and missing CpG. This has been correlated with the expression of L1 ORF1p 
(formerly called L1 p40 protein) using a semiquantitative evaluation of the 
immunohistochemical staining (from + = low expression to +++= high expression). 
4.5 Phenotype of hypomethylated normal SF.  
 
To explore whether a hypomethylating milieu is responsible for the activated phenotype of 
RASF, we continuously treated NSF (n=1) for three months with a non-toxic dose of the 
DNA hypomethylator 5-azaC, and analyzed the modification in gene expression using 
microarrays. 186 genes were more than two times upregulated during this condition. Many of 
these genes are implicated in RA, including interleukins, growth factors and their receptors, 
extracellular matrix proteins and enzymes, matrix degrading enzymes and inhibitors, adhesion 
molecules (Suppl. Table 1), protein kinases, transcription factors, components of Wnt, Ras 
and Rho-signaling pathways, and apoptosis-related proteins (Suppl. Table 2). The induced 
genes were categorized according to the occurrence of CpG islands in their respective 
promoters, in exons 1, or in both. Fifty-two of these genes had no CpG islands. One hundred 
and thirty-four of them have CpG islands in their promoters and/or exons 1 (P < 0.001). 
Transcription factors (18/22, P < 0.005) and adhesion molecules (10/11, P < 0.01) showed 
more CpG islands in their promoters and/or exons 1. We chose nine genes, which were  >5-
fold upregulated, and we measured their expression by flow cytometry in the presence and 
absence of 5-azaC. 
4.6 Upregulation of genes with CpG islands in their promoters. 
  
To confirm the 5-azaC expression microarray, OASF and RASF cultures (n=6, each) were 
treated for two weeks with a non-toxic dose of 5-azaC and the protein expression was 
analysed by FACS. Examples of genes with CpG islands in their promoters are CD10, CD29 
and CD130. These gene products were significantly increased after two weeks of treatment 
with 5-azaC (Fig. 5A). Moreover, these proteins were significantly more expressed on the cell 
surface of untreated RASF than on OASF.  
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4.7 Upregulation of genes with CpG islands in exon 1. 
 
 Several genes that showed a > 5-fold upregulation of mRNA had no clear CpG island in their 
promoters. However, some of them had a CpG island in exon 1. Examples were CD26, matrix 
metalloproteinase-14 (MMP-14) and transforming growth factor receptor 2 (TGF-R2) (Fig. 
5B). The baseline levels of CD26 and MMP-14 mRNA were the same in OASF and RASF. In 
presence of 5-azaC, however, CD26 and MMP-14 mRNA levels increased significantly over 
baseline in both OASF and RASF. TGF-R2 had a CpG island in exon 1, and its promoter 
showed an accumulation of CpGs. In OASF, 5-azaC increased the levels of expression 
significantly. However, in RASF, TGF-R2 expression on the cell surface was maximal in the 
absence and presence of 5-azaC.  
4.8 Upregulation of genes without CpG islands in their promoters.  
Several genes without CpG or increased frequency of CpGs up-regulate more than five-fold 
in the presence of 5-azaC, including CD36, CD46, cathepsin K (CK) (Fig. 5C). The basal 
expression of CD36 and CD46 on the cell surface was maximal in RASF and these values 
were significantly higher than those in OASF. Both are upregulated in OASF by 5-azaC. The 
baseline levels of CK were the same in OASF and RASF, but its expression was upregulated 
upon treatment with 5-azaC.  
4.9 Differences between OASF and RASF in the response to hypomethylation.  
 
In OASF, CD10, CD36 and CD46 showed significantly more increases in expression upon 5-
azaC (Fig. 5D). This was in large part because their expression was already maximal in 
RASF.  
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Figure 5. Protein expressions determined by flow cytometric analysis of gene products 
upregulated in a hypomethylating milieu in OASF and RASF.  
 
A-C) Confirmation of the data obtained by Affimetrix cDNA arrays for normal synovial 
fibroblasts continuously treated with 5-AzaC, inducing genomic hypomethylation. Data are 
presented as box plots of mean fluorescence intensity, where the boxes represent the 25th to 
75th percentiles, the lines within the boxes represent the median, and the lines outside the 
boxes represent the 10th to 90th percentiles. * p < 0.05, ** p < 0.01, *** p < 0.001, versus 
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OASF, by Mann-Whitney U-test (n=6 samples per group) . + p < 0.05, ++ p < 0.01, +++ p < 
0.001, versus untreated control by Wilcoxon signed rank test. 
D) Mean and SD percentages of increase from the baseline in gene expression in OASF and 
RASF. Significant differences in gene expression (n=6 patients to each diagnosis) between 
OASF and RASF in reaction to 5-AzaC treatment were observed for CD10, CD36 and CD46. 
MMP-14= matrix metalloproteinase 14; TGFβR2=transforming growth factor β receptor type 
II; CK=cathepsin K 
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5. Discussion 
 
Here we report that genomic hypomethylation developed in situ is conserved in RASF in vitro 
even after >5 passages, and confirm that the expression of LINE-1 proteins in RASF is 
associated with a partially hypomethylated LINE-1 promoter. The degree of CG 
hypomethylation (78% methylation in RASF, versus 85% in OASF ) in the LINE-1 promoter 
is similar to the degree of hypomethylation in tumor cells [9].  
 
It is essential to understand more about this global genomic hypomethylation. Pro-
inflammatory cytokines such as TNF, IL-1 and IL-6 have multiple influences on the 
pathogenesis of RA. IL-1 and IL-6 15] can affect genomic methylation. TNF, 
however, had not previously been associated with epigenetic changes. We observed that a 
physiologic dose of TNF accelerated the cell cycle, within 24 hours of exposure even more 
than IL-1 or PDGF. In OASF, stimulation of cell proliferation was accompanied by 
increased DNA methylation. This was not the case in RASF and therefore the relative degree 
of DNA hypomethylation remained in RASF treated with TNFor IL-1. As a consequence, 
it can be hypothesized that RASF become progressively more hypomethylated during 
inflammation. This results in further activation of genes in RASF. 
 
Previous reports have shown that deficiency of DNMT1 is associated with genomic 
hypomethylation [10, 16, 17]. DNMT1 interacts with PCNA at the DNA replication fork, and 
this system is responsible for the transmission of methyl marks to daughter cells. In RASF, 
however, the expression of DNMT1 appeared deficient, either in unstimulated cells or after 
exposition to pro-inflammatory cytokines. Thus, in RASF, a relative deficiency of DNMT1 
during cell proliferation could result in the observed genomic hypomethylation . 
 
Our work raises the question of whether the global genomic hypomethylation is accompanied, 
or followed by, specific promoter hypermethylation, since this is the case in various tumors 
[9]. At least one example has been reported in the literature, i.e. by silencing the death 
receptor 3 [18], which could, at least in part, explain the relative resistance to apoptosis 
reported for RASF in certain patients [2]. 
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In SF, the loss of methylation marks in daughter cells could cause an irreversible 
differentiation into an aggressive phenotype. Based on our observations, we hypothesized that 
NSF continuously treated with DNMTs-inhibitor 5-azaC will resemble RASF. Indeed, a large 
number of gene transcripts (73/186, 39%) found to be upregulated upon stimulation with 5-
azaC and detected in cDNA microarrays, were previously described to be involved in the 
pathogenesis of RA. It is known that DNA methylation silence genes with CpG island 
promoters. Therefore, we choose three genes in the list provided by the microarrays, which 
showed > 5 fold five upregulation of mRNA and the presence of CpG islands in their 
promoters, namely CD10, CD29 and CD130. We confirmed that they were expressed on the 
cell surface of RASF more than on the surfaces of OASF, and that their expression was 
increased within two weeks of treatment with a low dose 5-azaC. It is well established that 
RASF attach to cartilage through adhesion molecules, including CD29 and CD61 (1 and 3 
integrins) [7, 19]. Invasion of RASF into cartilage requires the availability of these two 
integrins [19, 20]. CD10, a neutral endopeptidase, is highly expressed on RASF [21], and 
presumably plays a critical role in the local regulation of peptide levels in the joint. IL-6 
signaling involves both a specific IL-6 receptor (IL-6R) and a ubiquitous signal-transducing 
protein, CD130 (gp130), which is also used by oncostatin M. Both IL-6 and oncostastin M are 
involved in the pathogenesis of RA [8, 22, 23]. 
 
We also evaluated the expression of genes that have no CpG island in their promoters, but do 
have a CpG island in exon 1, namely CD26, MMP-14 and TGF-R2. CD26 (dipeptidyl 
peptidase IV) was found to be highly expressed in RA synovial tissues [24] and in 
proliferating RASF [25]. The destruction of cartilage and bone in RA is in large part mediated 
by MMPs [20]. MMP-14 has a central role because it cleaves other pro-MMPs, and converts 
them into active forms. Inhibition of MMP-1 and/or MMP-14 results in a significant reduction 
of cartilage invasion by RASF [26]. Our results are in line with previous published data in 
pancreatic cancer cells showing that 5-azaC also upregulates the expression of MMP-14 and 
MMP-1 [27]. Expression of TGF-R2 was already maximal on RASF, as proposed earlier 
[28]. 
 
One fourth of genes (51/186, 27% in Suppl. Tables 1 and 2) that were upregulated upon 
treatment with 5-azaC in NSF contained no CpG island (e.g. CD36, CD46, CK, caspase-1 and 
IL-1R1). For example, CD36, abundantly expressed in RA synovial tissues, binds pro-
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inflammatory oxidized low density lipoproteins [29] and thrombospondin-1 [30]. CD46 is a 
C3b- binding protein, which could be involved in tissue damage in RA [31], whereas CK, a 
key enzyme in bone resorption, is highly expressed in RA synovial tissue, not only by 
osteoclasts, but also by RASF [32]. Caspase-1 (IL-1 converting enzyme), which activates 
IL-1 in the RA synovial tissue [33], is also upregulated in NSF by 5-azaC. IL-1 stimulates 
both the synthesis and the activity of MMPs involved in cartilage destruction [34]. 
 
The proportion of gene products that were upregulated in NSF upon 5-azaC treatment, which 
are involved in intercellular processes and interactions with the extracellular matrix, and 
which have been described in RA synovial tissues and/or RASF was particularly high (52/73, 
71% in Suppl. Table 1). These include twenty-two interleukins, growth factors and their 
receptors, thirteen extracellular matrix proteins and related enzymes; ten matrix-degrading 
enzymes and their inhibitors; and four adhesion molecules. Most importantly, among them, 
cathepsins, MMPs, mannosidase 1, carbonic anhydrases and ADAM12 are involved in joint 
destruction; and lysyl oxidase increased the crosslinking of mature collagen, an early step in 
cartilage destruction.  
 
Many of the gene products also upregulated in NSF upon 5-azaC treatment are involved in 
intracellular processes, and play a role in RA (20/94, 21% in Suppl. Table 2). They include 
four protein kinases, ten transcription factors, two proteins in the Wnt pathway, two proteins 
involved in the regulation of actin filaments and Rho signaling, and two regulators of 
apoptosis. Furthermore, transcription factors whose expression increased upon 5-azaC (18/22, 
82% in Suppl. Table 2) had CpG islands in their promoters and/or exon 1 more often than 
other genes revealed by the cDNA arrays. Many of them may play a role in RA, including 
Ets-related transcription factor, activating transcription factor 2 (ATF2; which binds to 
activator protein-1 (AP-1), C/EBP, NFAT5, CREB/ATF, HIF-2 and STAT1. The sustained 
upregulation of multiple signaling and transcription pathways in a hypomethylating milieu 
clearly could be responsible for the intrinsically activated phenotype of RASF. The cDNA 
arrays identified proteins that are implicated in the normal or pathological function of SF, 
including one recently reported as a potential autoantigen in RA, cartilage glycoprotein-39 
(gp-39) [35].  
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CD10, CD36 and CD46 were also more upregulated in OASF than in RASF upon 5-azaC. 
The expression of all other genes tested was upregulated to the same extent in OASF and 
RASF. Bisulfite sequencing of the CD10 CpG island, however, showed that it is 
hypomethylated even in NSF (data not shown). Therefore, the gene is regulated indirectly or 
by a methylation-independent mechanism. Other investigators have reported similar effects of 
5-azaC on myeloid leukemia genes [36]. CD46 and CD36 do not have a CpG island in their 
gene promoter, most likely they are regulated by indirect mechanisms. Other 5-azaC 
microarray studies have shown upregulation of genes in the absence of CpG islands in their 
promoters [37]. Thus, 5-azaC can apparently influence the expression of certain genes by 
different mechanisms. For example, it can affect histone modifications, up-regulate 
transcription factors, transcriptional repressors and/or the expression of microRNA[38, 39]. 
We have provided a list of transcription factors that could be candidates for future 
investigations (Suppl. Table 2).  
 
In summary, we report reduced 5-MeC DNA in RA synovial tissues and in cultured RASF. 
Specifically, the promoter of an LINE-1 element was partially demethylated, confirming the 
global genomic hypomethylation in RASF. Moreover, our observations suggested a 
progressive loss of methylation marks. It can be hypothesized that: 1) the loss of methylation 
marks could be responsible for the intrinsically activated and aggressive phenotype of RASF 
and 2) that tissue-specific transcription factors, which are not normally expressed in synovial 
tissues, are upregulated in the disease and can be responsible for the activation of many genes 
involved in the pathogenesis of RA. Moreover, genomic hypomethylation could explain the 
increased expression of multiple receptors, adhesion molecules, and matrix-degrading 
enzymes, which play a role in RA and explain the enhanced response of RASF to pro-
inflammatory cytokines, leading all together to joint destruction. Thus, the epigenetic 
modifications of RASF may be responsible, at least in part, for the fact that current therapies 
do not work in all patients and do not cure the disease yet.  
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Supplementary information 
 
Suppl. Table 1. Upregulated expression of genes involved in intercellular processes and interactions 
with the extracellular matrix (> 5-times open, > 2 times in parenthesis) in normal synovial fibroblasts 
cultured in a hypomethylating milieu, as revealed by Affimetrix cDNA arrays. The genes were 
grouped according to function and occurrence of CpG islands. Gene products previously associated 
with rheumatoid arthritis are marked with an * (PubMed).  
 
 
                   No CpG island      CpG island                  CpG  island exon 1       CpG island promoter/exon 1 
 
In
te
rl
eu
ki
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/g
ro
w
th
 fa
ct
or
s a
nd
 
re
ce
pt
or
s 
     
     IL-1R1*        CD130/gp130*    TGF-R2*  CD232/Plexin C1 
     IGF-1*        (Activin A-RIIA)*    TFPI-2  (EGF-R v-erb-B)* 
     PDGF-R-like*       (IL-13R1)*                  Neuromedin B                (DCBLD2) 
     (Caspase-1)*        (Proenkephalin A)*      (Angiotensin II-R1)*  (IFITM1) 
     (CCL4)*                (TGF-R1)*                 (EGF-like EDIL3)  (Osteocalcin)* 
     (CCRL1)*        (Pentraxin 2) 
     (CD105/Endoglin)*                    (Sortilin 1) 
     (FAP)*                     (VEGF-A)* 
     (IL-12A)* 
     (IL-13R2)* 
     (PHRH)* 
     (TGF-R3)* 
 
E
C
M
 p
ro
te
in
s a
nd
 
en
zy
m
es
 
     
     CD36*        CD10*                  CD26*                            (CD142/tissue factor F3)* 
     CD46*        Fibronectin 1*    (SCARB1)               (Fibronectin FLRT2) 
     gp-39*                   (APLP2)     (Brevican)               (Fibronectin FNDC3A) 
     Laminin 4        (Bamacan)     (Collagen VI 1)* (Glypican 3)* 
     Proteoglycan 4      (USP10)     (Lysyl oxidase)* (Mannose-binding lectin)54 
     (Asporin)*        (USP34)     (Thrombomodulin)* (Periplakin) 
     (Dermatopontin) 
    (Sarcoglycan ) 
    (Utrophin) 
 
M
M
Ps
  a
nd
 
in
hi
bi
to
rs
 
 
    Cathepsin K*        (MAN1A1)*      MMP-14*                      Carbonic anhydrase XII* 
    MMP-1*        (Cathepsin L)*   Cathepsin H* 
   (Cathepsin S)*        (TIMP-3)*  GNS 
        (ADAM12)* 
        (Serine protease 12) 
 
A
dh
es
io
n 
m
ol
ec
ul
es
 
 
    (CLEC2B)       CD29/1 integrin*        (Fibulin 1)  Protocadherin C3 
         (Protocadherin 9)      (Protocadherin 12) (CD61/3 integrin)* 
          (Protocadherin A3) (8 Integrin) 
          (Tetraspanin 6)* (Tetraspanin 2)* 
O
th
er
s      Apolipoprotein E*                   Cyclooxygenase 1* 
                     Glutathione peroxidase 3* 
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Suppl. Table 2. Upregulated expression of genes involved in intracellular processes (> 5-times open, 
> 2 times in parenthesis) in normal synovial fibroblasts cultured in a hypomethylating milieu. 
 
 
 
 
                   No CpG island      CpG island                  CpG  island exon 1       CpG island promoter/exon 1 
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  (Kynureininase)      (PRKAR1A)*  (TNIK)*                          (MAPK14 / p38а)* 
  (TANK)                 (PRKG1)*  (RIPK5)              (MAPKKK8) 
  (GIT2)       (TRAF3 IP2)  (MAPKKKK5) 
     (MAPKK2) 
 
 
Tr
an
sc
ri
pt
io
n 
fa
ct
or
s a
nd
 
re
gu
la
to
rs
 
 
     
   TPR-MET*      (ATF2)*  (AFF2)                (CREBZF)* 
   (ELF1)*                (BACH1)  (C/EBP)*  (GTF2I) 
   (ODZ1)                 (BCLAF1)  (NFAT5)*  (GTF3C2) 
   (RUNX1)*      (MBTPS1)  (SOX4)                (HIF2)* 
       (TCFL2)  (STAT2)*  (MBTPS2) 
                      (PHTF2) 
        (SMAD2)* 
        (STAT1)* 
 
 
W
nt
/F
ri
zz
le
d 
sig
na
lli
ng
 
 
 
   Wnt1 IP2                  SFRP4*                  (SFRP1)* 
   
 
A
ct
in
 fi
la
m
en
ts
/ R
ho
 
sig
na
lin
g 
 
    Gelsolin*    (KLHL24)  (ROCK2) 
    (ARHGAP1)    (RHOBTB3)  (Podoplanin) 
    (ARHGEF3)    (MFAP3)  (SMARDCD2) 
    (Caldesmon 1)    (Myomegalin) 
    (PHACTR2) 
    (Tenascin C)*  
 
 
A
po
pt
os
is
  
      
                                          (Formin BP3)  (MAGD4)  (API5) 
   (RNF6)     (PIP4K2B) 
   (TXNIP)* 
   (WWOX)* 
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O
th
er
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    ATP13A3  DHX9  EIF4EBP2     ASPHD1 
    ATP2A1  PTPN12  (ARL4C)     CRISPLD2 
   COPA   (CHP1)  (KCND2)     (ATP2A2) 
   EVI2A  (FBOX38) (RAB3B)     (ATP6V1C1) 
   EVI2B                (FKNB15) (SF3B1)                    (CACNA2D1) 
   SLC16A7  (PLD1)  (SLC16A2)      (Cyclin G2) 
   (DBT)   (RAB27A)        (ENPP1) 
   (RBM9)  (SEL1L)                                   (GNA13) 
   (REP-1)  (STEAP1)        (PCM1) 
   (SERPINF1)           (PTPN11) 
   (SNAP23)           (ZKSCAN1) 
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1. Abstract 
 
In the search for specific genes regulated by DNA methylation in RA, we investigated the 
expression of CXCL12 in SF and the methylation status of its promoter and determined its 
contribution to the expression of matrix metalloproteinases (MMPs). 
 
DNA was isolated from SF and methylation was analysed by bisulfite sequencing and McrBC 
assay. CXCL12 protein was quantified by ELISA before and after treatment with 5-
azacytidine. RASF were transfected with CXCR7-siRNA and stimulated with CXCL12. 
Expression of MMPs was analysed by Real-Time PCR.  
 
Basal expression of CXCL12 was higher in RASF than osteoarthritis (OA) SF. 5-azacytidine 
demethylation increased the expression of CXCL12 and reduced the methylation of CpG 
nucleotides. A lower percentage of CpG methylation was found in the CXCL12 promoter of 
RASF compared to OASF. Overall, we observed a significant correlation in the mRNA 
expression and the CXCL12 promoter DNA methylation. Stimulation of RASF with CXCL12 
increased the expression of MMPs. CXCR7 but not CXCR4 was expressed and functional in 
SF. 
 
We show here that RASF produce more CXCL12 than OASF due to promoter methylation 
changes and that stimulation with CXCL12 activates MMPs via CXCR7 in SF. Thereby we 
describe an endogenously activated pathway in RASF which promotes joint destruction.  
   Chapter 3                                                         Karouzakis E. et al. Genes and Immunity 2011 
 
 
72
2. Introduction 
 
A variety of studies describe an activated phenotype of synovial fibroblasts (SF) in 
rheumatoid arthritis (RA) which is characterized by a changed morphology, deranged 
apoptotic behaviour, and increased invasive properties [1]. Recently, we found that epigenetic 
changes might contribute to these phenotypic changes in RASF. We could show that DNA of 
RASF is globally hypomethylated when compared to osteoarthritis (OA) SF or normal SF and 
that less DNA methyltransferase DNMT1, the enzyme responsible for DNA de novo 
methylation is present in RASF [2]. DNA methylation is well known to regulate gene 
expression. Transcriptional regulation by DNA methylation occurs in CpG rich regions of 
gene promoters, so called CpG islands. Methyl CpG binding proteins bind to methylated CpG 
islands and together with chromatin remodelling enzymes cause gene silencing [3]. In the 
normal genome, DNA methylation regulates gene expression to form tissue specific 
expression  patterns [4]. Aberrant DNA methylation was found in various pathologies 
including cancer and autoimmune diseases [5, 6]. 
CXCL12, also known as stromal-derived factor-1 (SDF-1) is a key player in the trafficking of 
lympho- and hematopoietic progenitor cells and in the early development and regeneration of 
tissues [7]. Moreover, the secretion of CXCL12 is increased after tissue damage by hypoxia, 
toxins or irradiation, leading to the immigration of progenitor cells expressing the CXCL12 
receptor CXCR4 [8]. A second receptor for CXCL12, CXCR7 has only most recently been 
identified and has been implicated in tumor growth and metastasis [9-11]. Elevated levels of 
CXCL12 were found in patients with multiple sclerosis, inflammatory myopathies, 
spondyloarthropathies and RA [12-17]. Levels of CXCL12 in the synovial fluid of RA 
patients are around 10 times higher than in healthy joints and reach a mean of 750 ng/ml [16]. 
It is understood that CXCL12 drives chronic inflammation by attraction of monocytes and 
lymphocytes into the joint and by stimulation of synovial fibroblasts to produce pro-
inflammatory cytokines [17-20]. Previous studies also showed that cultured RASF produce 
more CXCL12 than normal or OA synovial fibroblasts [16, 21]. 
Based on these results, we analyzed in the current work whether expression of CXCL12 in 
RASF is modified by changes in DNA methylation. Furthermore, to elucidate CXCL12 
signaling pathways we looked at the expression of CXCR7 in synovial fibroblasts and tested 
whether CXCR7 mediates the production of matrix-metalloproteinases (MMPs) after 
CXCL12 stimulation in RASF. 
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2. Material and Methods 
 
2.1 Patients and tissue preparation: Synovial tissues were obtained from trauma patients 
(normal synovial fibroblasts, NSF, n=2), RA n=14 and OA n=11 patients undergoing joint 
replacement surgery at the Schulthess Clinic Zurich after written consent (Table 1).  All RA 
patients fulfilled the American College of Rheumatology criteria for the classification of RA 
[22]. Normal lung fibroblasts were isolated from open lung biopsies of patients suspected 
with cancer but with a negative diagnosis. Synovial fibroblasts and normal lung fibroblasts 
were isolated and cultured as described previously [23]. 
 
2.2 Bisulfite sequencing. Genomic DNA was prepared from synovial fibroblasts using the 
QiAmp DNA blood Mini kit (Qiagen, Hombrechtikon, Switzerland). The DNA (1µg) was 
bisulfite modified using the EpiTect bisulfite kit (Qiagen). Two rounds hemi-nested PCR 
amplification of bisulfite modified DNA (2 µl) was performed using the AmpliTaq Gold 
polymerase (Applied Biosystems, Rotkreuz, Switzerland). The PCR cell cycle program was 
95°C 4 min ; 95°C 30s, 52°C 90 sec, 72°C 2 min x 5 ; 95°C 30sec, 52°C 90sec, 72°C 90 sec x 
25 ; 72°C 4 min. Primers were designed for two regions of the CXCL12 CpG island promoter. 
The forward 5-GTT TGT GAT TAG TTT ATT TTA TTA-3, reverse 5-CTA AAT AAA 
AAC CAA TAA AAA AC-3 and hemi-reverse 5-AAA AAA TCC TAC TTT CTA TAC-3 
bisulfite sequencing primers amplified the region -741bp to -477bp  and the forward 5-GTT 
TTT TAT TGG TTT TTA TTT AGT TTT-3, reverse 5- TAC CTC CAC CCC CAC TAT AT-3 
and hemi reverse 5- GAG TTT GAG AAG GTT AAA GGT-3 bisulfite sequencing primers 
amplified the region -244bp to +272bp. The computer software MethPrimer predicted CpG 
islands with the following criteria: island size >100, GC content > 50 % and Obs/Exp >0.6 
and designed bisulfite primers for DNA methylation analysis [24]. The PCR purified 
fragments were cloned using the Qiagen PCR cloning handbook according to manufacturer 
instructions (Qiagen). Positive clones were sequenced (Microsynth, Balgach, Switzerland). 
The data was analysed using the BiQ analyzer software [25]. 
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Table 1.  Characteristics of the study patients  
 Diagnosis Patient 
 Number 
 
Age  
(years) 
Gender  Disease 
duration 
(years) 
NSAIDs DMARDs RF pos        
(>20 I.U.) 
RA 1 55 f 18 + steroids + 
2 64 f 9 - 
MTX 
hydroxychloroquine 
steroids + 
3 70 m 4 + steroids + 
 4 65 f 15 - MTX + 
 5 52 f 19 - Actemra,MTX + 
 6 69 f 28 - Humira + 
 7 45 f 17 - Salazopyrin,Arava + 
 8 65 m 15 - MTX + 
 9 52 f 21 - Arava NA 
 10 66 f 46 - MTX + 
 11 67 f 37 - Mabthera + 
 12 66 f 16 - Arava, Prednison + 
 13 73 f 7 - Prednison + 
 14 79 f 30 - Prednison NA 
OA 1 95 f NA - - NA 
 2 70 f NA + - NA 
3 53 f NA + - NA 
 4 61 f NA - - NA 
 5 71 m NA - - NA 
 6 73 f NA - - NA 
 7 70 m NA - - NA 
 8 82 f NA - - NA 
 9 62 m NA - - NA 
 10 79 m NA - - NA 
 11 72 f NA - - NA 
___________________________________________________________________________
RA: rheumatoid arthritis; OA: osteoarthritis; f/m: female/male; NSAIDs: non-steroidal anti-
inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs; RF pos: rheumatoid 
factor positivity; MTX: methotrexate; NA : not assessed. 
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2.3  McrBC digestion and quantitative Real-time PCR. The CXCL12 promoter DNA 
methylation was determined by methylation-sensitive McrBC-PCR assay. Genomic DNA 
(1μg) was sonicated using the Diagenode bioruptor (10 min, 15 sec on and 15sec off). The 
sonicated DNA was digested with 10 units of McrBC or mock undigested in a 50μl reaction 
mixture containing 1x NEB2 buffer, 10mM GTP and 0.1mg/ml BSA. The restriction 
digestion reaction was incubated at 37 oC overnight and then the reaction was deactivated 
with heating at 65 oC for 20 min. The McrBC treated DNA and mock samples were purified 
using Qiagen PCR purification protocol kit. Quantitative SYBR green PCR using the 
CXCL12 promoter (-741 to -477) primers: Forward CAC CAT TGA GAG GTC GGA AG, 
Reverse AAT GAG ACC CGT CTT TGC AG, was carried out with the McrBC digested and 
mock samples. McrBC cleaves methylated DNA strands and inhibits PCR amplification. In 
contrast, unmethylated DNA prevents McrBC cleavage and can be measured by quantitative 
PCR. Mock undigested DNA is considered as total amount of DNA used in the reaction. 
Methylated DNA will have decreased Ct values after McrBC digestion. The Real-time PCR 
results were normalized with the mock treated sample DNA (deltaCt) and presented as fold 
induction of PCR recovery after digestion with McrBC. 
 
2.4 Stimulations. RASF and OASF were seeded at low density 24h before treatment. RASF 
were stimulated with 100 ng/ml recombinant CXCL12 (Peprotech, London, UK). OASF were 
treated with 0.5 μM or 1 μM 5-azacytidine (Sigma) for 6 days. The cell culture medium was 
changed every 24h and replaced with new 5-azaC.  
 
2.5 Transfection of CXCR7 small interfering RNA (siRNA). siRNA for CXCR7 and 
double stranded siRNA without homology to mammalian genes (negative control) (both from 
Qiagen) were used for silencing experiments. Also, transfection without siRNA (mock) was 
performed to determine whether the experimental set-up causes unspecific effects. The 
transfections were done by electroporation (Nucleofector, Lonza, Cologne, Germany) using 
transfection reagents for primary mammalian fibroblasts (Basic Nucleofector® Kit; Lonza) at 
a concentration of 0.9 µg siRNA/5x105 cells. Transfected RASF were cultured for 48h before 
efficiency of knock-down was measured by Real-time PCR, FACS and Western blot or before 
stimulations were begun. 
 
2.6 RNA isolation and quantitative Real-time PCR. Total RNA was isolated using the 
RNeasy Miniprep kit (Qiagen) including DNase treatment. RNA was reverse transcribed 
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using random hexamers and multiscribe reverse transcriptase (both Applied Biosystems, 
Rotkreuz, Switzerland). Samples without addition of reverse transcriptase served as negative 
control (non RT). Relative quantification of mRNA levels by TaqMan®/SYBRGreen® Real-
time PCR was done using eukaryotic 18S ribosomal RNA as endogenous control (Applied 
Biosystems). The differences of the comparative threshold cycles (Ct) of sample and 18S 
cDNA were calculated (dCt). Relative expression levels were calculated following the 
formula ddCt = dCt (sample stimulated) - dCt (sample unstimulated). Relative expression was 
calculated using the expression 2-ddCt. The sequence of the primers used for measuring MMP-
1, MMP-2, MMP-3, MMP-9, MMP-13, MMP-14, TIMP-1, TIMP-2, TIMP-3 were previously 
described [26]. 
 
2.7 PCR. mRNA was reverse transcribed using oligo dT and Moloney Murine Leukemia 
Virus reverse transcriptase (both Applied Biosystems, Rotkreuz, Switzerland). PCR was 
performed on a C1000™ Thermal Cycler (Bio-Rad laboratories, Hercules, CA) with the 
following primer pairs and protocols designed to detect the 4 different CXCR4 mRNAs as 
published on the National Center for Biotechnology Information AceView database. CXCR4 
transcript 1: forward primer GGAAAAGATGGGGAGGAGAG, reverse primer 
CACTTCCAATTCAGCAAGCA; CXCR4 transcript 2: forward primer 
CAGCAGGTAGCAAAGTGACG, reverse primer GTAGATGGTGGGCAGGAAGA; 
CXCR4 transcript 3: forward primer AAGGGTCACCGAAAGGAGTT, reverse primer 
GAAGAGACCGGTGGTCTGAG; CXCR4 transcript 4: forward primer 
GTTAAGCGCCTGGTGACTGT, reverse primer GGTAACCCATGACCAGGATG. 94°C 
5min, 40 cycles with 94°C 30s, 58°C 30s, 72°C 30s and a final elongation of 5min with 72°C. 
β-microglobulin: forward primer AAGATTCAGGTTTACTCACGTC, reverse primer 
TGATGCTGCTTACATGTCTCG. 94°C 5min, 35 cycles with 94°C 30s, 55°C 30s, 72°C 30s, 
final elongation 72°C 5min. Reaction products were separated on a 1.5% agarose gel and 
signals were visualized using ethidium bromide.  
 
2.8 Western blot analysis. Whole cell lysates were prepared by lysing cells in 2x Laemmli 
buffer. Proteins were separated on a 10% SDS-polyacrylamide gel and transferred to Protran 
nitrocellulose membranes (Schleicher & Schüll, Dassel, Germany). Membranes were blocked 
for 1h at room temperature in 5% nonfat dry milk with 0.05% Tween 20 in TBS and were 
incubated overnight with polyclonal rabbit anti-human CXCR7 (2.8 µg/ml; Abcam, 
Cambridge, UK). To ensure specificity of the CXCR7 antibodies, blots were incubated with 
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CXCR7 antibodies which were pre-incubated for 1h at 37°C with or without 10 µg/ml of a 
synthetic CXCR7 peptide (10 µg/ml; Abcam). Afterwards, membranes were incubated with 
HRP-conjugated secondary antibodies (Jackson Immunoresearch, Suffolk, UK). Bound 
antibodies were visualized using enhanced chemiluminescence (Amersham Bioscience, 
Otelfingen, Switzerland). Equal protein loading was confirmed using mouse anti-human -
tubulin antibodies or Ponceau solution (Sigma-Aldrich, Basel, Switzerland).  
 
2.9 Flow Cytometry. RASF were detached from the culture flask with accutase (PAA 
Laboratories, Linz, Austria), washed with PBS/1%FCS and incubated with 20 µg/ml of rabbit 
anti-human CXCR7 (Abcam, Cambrige, UK) or of rabbit IgG for 45 minutes at 4°C. Cells 
were washed with PBS/1%FCS and subsequently incubated with FITC-labeled goat anti-
rabbit IgG for 45 minutes at 4°C. Washing steps were repeated twice before analysis of the 
cells in the flow cytometer (FACSCalibur). Data were processed using CellQuest software 
(BD Biosciences, San Diego, CA). 
 
2.10 ELISA. Synovial fibroblasts were seeded at 1 x 105/ml DMEM and CXCL12 was 
measured after 24h (Figure 1B) or at 2 x 105/ml DMEM and CXCL12 was measured after 24h 
and 96h (Figure 5C) in the supernatants with the DuoSet® ELISA development system (R&D 
Systems, Abingdon, UK) according to the manufacturer’s instructions. 
 
2.11 CXCL12 blockade. RASFs (2 x 105) were incubated with 1 μg/ml neutralizing anti-
human CXCL12 antibodies (R&D Systems) or IgG control. Fresh antibodies or control was 
added after 48h.Cells were lysed after 24h or 96h. 
 
2.12 Statistical analysis. All data are expressed as mean ±SEM. Statistical analysis was 
performed using GraphPad Prism software, version 4.03 (GraphPad System, San Diego, CA). 
For analysis between different groups, the Mann-Whitney U, for paired analysis Wilcoxon 
signed rank test was used. P values less than 0.05 were considered significant. 
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3. Results 
3.1 RASF upregulate CXCL12 mRNA and protein expression. 
To analyse the basal expression of CXCL12 expression in RASF and in OASF, we measured 
CXCL12 mRNA and protein levels in cell culture supernatants after 24h. RASF express 
significantly more CXCL12 mRNA than OASF and NSF (RASF 6.9±0.3 dCt, n=11; OASF 
8.3±0.5 dCt, n=8; NSF 7.5 dCt, n=1; p<0.028) (Fig 1A). Furthermore, we observed that the 
mRNA expression of CXCL12 was positively correlated with the C-reactive protein, a marker 
of inflammation marker in these patients (r =-0.64, p<0.01). RASF produced with 85±12 
pg/ml also significantly more CXCL12 protein than OASF with 52 ±10 pg/ml (Fig.1B).  
 
 
 
 
Figure 1. RASF express more CXCL12 mRNA and secrete more protein than OASF. A) 
RASF (n=11, ■) expressed significantly more CXCL12 mRNA than OASF (n=8, ●) and NSF 
(n=1, ●).  The mRNA expression of CXCL12 correlated with the patients CRP levels. B) 
ELISA was used to analyse the amount of CXCL12 release in RASF (n=9) and OASF (n=7) 
cell culture supernatants. RASF released significantly more CXCL12 than OASF. * p<0.05 
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3.2 DNA methylation regulates the promoter of CXCL12 
To investigate whether changes in DNA methylation might influence expression of CXCL12 
in RASF, we first tested whether the CXCL12 promoter can be regulated by DNA 
methylation. Computational analysis predicted that there are CpG islands upstream of the 
transcription initiation site of the CXCL12 promoter (Fig. 2A). We further analysed the 
region that is 100 bp upstream of exon 1 (-741bp to -477bp) and the region that spans exon 1 
(-244bp to +272bp) by bisulfite sequencing. Our findings showed that NSF have a high 
percentage of methylated CpG nucleotides in the promoter upstream region from -741bp to -
477bp, while in the region -244 to +272, that spans the transcriptional initiation site and exon 
1, all the CpG nucleotides were unmethylated (Fig. 2B). To see whether demethylation of the 
heavily methylated CpG rich region would influence CXCL12 expression, we treated OASF 
with different doses of the demethylating drug 5-azaC and found dose dependent upregulation 
of CXCL12 protein secretion (Fig. 2C). Furthermore, bisulfite sequencing analysis showed 
demethylation of the CXCL12 promoter (-741bp to -477bp) with 1 μM 5-azaC (Fig. 2D). In 
addition, the mRNA expression of CXCL12 correlated with the methylation levels of the 
CXCL12 promoter (r =0.60, p<0.04) as show my McrBC digestion assay (Fig. 2E).Taken 
together, the results of figure 2 indicate that expression of CXCL12 is regulated by 
methylation of its promoter, and accordingly can be increased by demethylation.  
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Figure 2. Expression of CXCL12 is regulated by DNA methylation. 
A) Computational analysis of the CXCL12 promoter region. (blue coloured regions: CpG 
islands) The percentage of C and G nucleotides (CG %) are shown 2000 basepairs upstream 
of the transcription initiation site (arrow) and exon 1. Bisulfite sequencing primers were 
designed to analyse region -741bp to -477bp and -244bp to +272bp of the CXCL12 promoter. 
B) Methylated CpG dinucleotides were found in the region -741bp to -477 of NSF (n=1). 
Each circle represents a methylated (black) or unmethylated (white) CpG dinucleotide. Every 
row represents a different clone.  C) After treatment of OASF with 0 , 0.5 and 1 μM 5-azaC 
for 6 days, amounts of CXCL12 were determined by ELISA (n=4). 5-azaC treatment induced 
dose dependent release of CXCL12 (* p < 0.05).  D) 5-azaC demethylates the analysed 
promoter region as shown by bisulfite sequencing (n=1 OASF, 6 clones were sequenced). E) 
McrBC digestion and CXCL12 promoter (-741bp to -477bp) quantitative PCR of RASF 
(n=11) genomic DNA. Negative correlation between CXCL12 mRNA expression and 
CXCL12 promoter DNA methylation was shown in RASF. 
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3.3 Demethylation of CXCL12 promoter upregulates CXCL12 mRNA expression. 
To investigate whether the methylation status of the CXCL12 promoter is altered in 
fibroblasts of RA patients, we compared the percentage of CpG methylation between RASF 
NSF, OASF and normal lung fibroblasts (Fig. 3A, B). First, a group of 4 pooled RASF 
patients and a group of 3 pooled OASF patients were compared. The analyzed promoter 
region of CXCL12 had significantly less CpGs methylated in the RASF group than in the 
OASF group (RASF 21% ± 7.2 versus OASF 42% ±7.8). We then analysed whether the 
results from the pooled groups would be reflected in individual patient’s analysis. CXCL12 
promoter had similar changes as seen in the pooled samples (RASF 1-2 27% ± 4.8 versus 
OASF 1-2 46% ± 5.6 ). The CXCL12 promoter in NSF cell cultures was strongly methylated 
(NSF1 54% and NSF2 60%). As expected, the CXCL12 promoter in lung fibroblasts was 
similarly strongly methylated as in NSF or OASF. The above results suggest that normally the 
expression of CXCL12 is repressed by methylation in fibroblasts, but that an epigenetic defect 
in synovial fibroblasts of RA patients causes an intrinsically increased expression of 
CXCL12. 
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Figure 3.  RASF have low levels of CXCL12 promoter DNA methylation.  
A) Bisulfite sequencing of CXCL12 promoter region (-741 to -477) in RASF, OASF, NSF 
and lung fibroblasts. Nine to ten clones were sequenced from two independent RASF and 
OASF patients or from a pooled group of four RASF and three OASF patients. In addition, 
three to six clones were sequenced from two NSF and one normal lung fibroblast culture. B) 
Summary of the data as percentage of CpG methylation between pooled fibroblasts cell types 
shows that RASF have significantly lower percentage of DNA methylation than OASF. C) 
Summary of the data as percentage of CpG methylation between individual fibroblasts cell 
types shows that RASF have significantly lower percentage of DNA methylation than OASF. 
The methylation percentage was calculated in B and C separately for each clone and the 
average of total number of clones was plotted in the histogram graph. * p < 0.005.   
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3.4 Overexpression of CXCL12 induces functional changes in RASF 
Stimulation of synovial fibroblasts, chondrocytes and osteoclasts with CXCL12 in vitro was 
previously found to induce the expression of matrix degrading enzymes [16, 27, 28]. Since 
demethylation induces CXCL12 overexpression, we measured mRNA expression of the 
collagenases MMP-1 and MMP-13, the gelatinases MMP-2 and MMP-9, stromelysin (MMP-
3), and the matrix-bound MMP-14 after stimulation with CXCL12 for 24h in RASF. In 
addition, we looked at the mRNA expression of the tissue inhibitors of matrix 
metalloproteinases (TIMPs) -1, -2, and -3. CXCL12 levels in joints of RA patients have been 
measured to be on average 375 and 750 ng/ml respectively [16, 29]. We stimulated RASFs in 
vitro with 100 ng/ml. Stimulation with CXCL12 selectively and significantly increased the 
expression of MMP-1 by 6 ±3 fold, of MMP-3 by 2 ±0.2 fold and of MMP-13 by 4 ±1 fold 
(Fig.4A). In contrast, CXCL12 neither influenced the expression of MMP-2, MMP-9, or 
MMP-14, nor did it change the expression levels of TIMPs. 
 To see whether endogenous production of CXCL12 by RASFs in culture would be enough to 
stimulate the expression of MMPs, we increased the concentration of CXCL12 in the cell 
culture supernatants by increasing the ratio between seeded cells and medium and by 
prolonging incubation times and added an CXCL12 neutralizing antibody or IgG control (Fig. 
4B). Expression of MMP-1 was decreased 26% after 24h, and 42% after 96h incubation by 
CXCL12 blockade compared to IgG control. 
We then addressed the question whether CXCL12 signals via CXCR4 or the newly found 
CXCL12 receptor CXCR7 in synovial fibroblasts. Transcription of the CXCR4 gene produces 
4 different mRNAs which putatively encode 4 different isoforms of the protein. We analyzed 
the expression of these 4 transcripts in PBMCs, synovial fibroblasts, synovial tissues and 
HeLa cells. None of the tested synovial fibroblasts expressed any transcripts for CXCR4. In 
PBMCs all four transcripts were amplified, whereas HeLa cells expressed transcript 1, 2 and 
4. In RA synovial tissues transcripts 1 and 2 were detectable, probably due to the infiltration 
of lymphocytes, since in OA synovial tissues none of the transcripts was found (Fig.4C). In 
contrast to CXCR4, CXCR7 protein was constitutively expressed in synovial fibroblasts 
(Fig.4D). 
We then silenced the expression of CXCR7 with siRNA (Fig.5A) and examined whether this 
would influence the induction of MMPs in RASF after stimulation with CXCL12. After 
transfection of siRNA targeting CXCR7, no increase in the mRNA expression of MMP-1, 
MMP-3 and MMP-13 was seen anymore after stimulation with CXCL12 (Fig.5B). From these 
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experiments we conclude that CXCR7 is functionally important in synovial fibroblasts and its 
activation by CXCL12 leads to expression of MMP-1, MMP-3 and MMP-13. 
 
 
 
Figure 4.  Overexpression of CXCL12 induces MMPs expression. A) Expression of MMP-
1, MMP-3 and MMP-13 transcripts are significantly increased after stimulation of RASF with 
CXCL12 (n = 6). Data are presented as x fold change after stimulation relative to 
unstimulated cells. B) Time dependent release of CXCL12 protein in cell culture supernatants 
and inhibition of MMP1 expression using a CXCL12 blocking antibodies (n=3) C) 
Expression of the four known CXCR4 mRNA transcripts 1-4 by conventional RT-PCR. D) 
Western blot showing the expression of CXCR7 protein in HeLa cells and RASF obtained 
from 4 different patients; patient’s samples were loaded twice on a 10% gel and the 
membrane was cut. The left side was incubated with anti-CXCR7 antibodies, the right side 
with anti-CXCR7 antibodies pre-incubated with CXCR7 synthetic peptide; α-tubulin (tub) 
served as a loading control.  
 
We then silenced the expression of CXCR7 with siRNA (Fig.5A) and examined whether this 
would influence the induction of MMPs in RASF after stimulation with CXCL12. After 
transfection of siRNA targeting CXCR7, no increase in the mRNA expression of MMP-1, 
MMP-3 and MMP-13 was seen anymore after stimulation with CXCL12 (Fig.5B). From these 
   Chapter 3                                                         Karouzakis E. et al. Genes and Immunity 2011 
 
 
85
experiments we conclude that CXCR7 is functionally important in synovial fibroblasts and its 
activation by CXCL12 leads to expression of MMP-1, MMP-3 and MMP-13. 
 
 
Figure 5. CXCR7 is functional in SF. A) Expression of CXCR7 after silencing was 
measured on mRNA level (left panel) and on protein level (right panels). Western blot and 
FACS analysis confirmed silencing of CXCR7 after transfection with siRNA when compared 
to cells transfected with control siRNA. Grey filled line: rabbit IgG; black filled line: CXCR7 
siRNA transfected RASF; black open line: scrambled control siRNA transfected RASF. B) 
MMP-1, MMP-3 and MMP-13 levels in control transfected RASF (sc) and CXCR7 silenced 
RASF (siCXCR7) with and without CXCL12 stimulation (n = 7). All values are the mean and 
SEM. 
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4. Discussion 
 
In the current paper we show that the high expression of CXCL12 in RASF is due to an 
epigenetic alteration and that high amount of CXCL12, as found in the joints of RA patients 
lead to increased expression of MMPs and to joint destruction. 
 
 In cancer, both DNA hypomethylation and hypermethylation have been shown to occur [30, 
31]. The promoters of p16 or the DNA repair genes MLH1 and BRCA1 for instance have 
been shown to be silenced by increased DNA methylation in cancer cells [32]. Global 
hypomethylation was correlated with demethylation of repetitive sequences e.g. Sata, D4Z4, 
NBL2 and transposable elements e.g. LINE-1 [33, 34]. We and others have reported global 
hypomethylation of synovial fibroblasts in RA and CD4 T cells in SLE [2, 35]. We also 
showed that this global hypomethylation affects the promoter of LINE-1 transposable element 
in RASF and that continuous treatment of NSF with 5-azaC induced changes in gene 
expression that resemble the activated status of RASF such as increased production of MMP-
14, CD29 and cathepsins [2]. Also in SLE, hypomethylation of specific gene promoters have 
been shown to contribute to the pathogenesis of the disease [35]. Similar to the approach of 
our current study it was shown that normal T cells treated with 5-azaC upregulated LFA1, 
CD70 and perforin and that the CpG islands in the promoters of these genes were 
hypomethylated in T cells of SLE patients [36-38]. DNA methylation of promoter sequences 
can change the binding of transcription factors. Transcriptional regulation studies of the 
CXCL12 promoter revealed the presence of E-box consensus sequences which are binding 
sites for multiple transcription factors such as bHLH, NFAT, SP1 and HIF1α. [39-41]. The 
low methylation levels observed in the CXCL12 promoter in RASF could change the binding 
of these transcription factors and thereby increase gene expression. In healthy fibroblasts, the 
CXCL12 promoter was strongly methylated in our study. In cancers, it has been shown that 
DNA hypermethylation of the CXCL12 promoter in colon carcinomas, mammary carcinomas 
and the MCF7 breast cancer cell line inhibits tumor metastasis.  
 
In the current study basal levels of CXCL12 were higher in RASF compared to OASF. Even 
though these changes were not dramatic, we believe that they are of clinical significance since 
CXCL12 expression positively correlated with levels of CRP. CXCL12 is expressed at high 
levels in RA, and it has been implicated in a number of pathogenic events such as recruitment 
and persistence of inflammatory cells in the synovium, as well as production of cytokines and 
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matrix degrading enzymes [16, 17, 20, 28, 42]. The role of CXCL12 in cartilage destruction 
was further supported by in vivo experiments which showed that CXCL12 antagonists inhibit 
fibroblast-induced cell infiltration in immunodeficient mice [43]. CXCL12 can signal via 
CXCR4 and CXCR7. Expression of CXCR4 has been detected in synovium of healthy 
individuals as well as in OA and RA patients [20, 44]. Controversial data is published 
regarding the expression of CXCR4 in synovial fibroblasts. Whereas Garcia-Vicuna et al 
detected CXCR4 in synovial fibroblasts, Kanbe et al did not [16, 28]. We also could not 
detect mRNA for CXCR4 in synovial fibroblasts of RA or OA patients. Since, pancreatic 
cancer cells do not express CXCR4 due to promoter hypermethylation, CXCR4 silencing 
could also occur by DNA methylation in synovial fibroblasts. CXCR7, previously named 
RDC1 was first classified as an orphan receptor since no ligand could be found [45]. Recent 
publications have then related this receptor to cell recruitment, migration and proliferation 
after binding of CXCL12 in various cell types [9, 46, 47]. In the present study, we show that 
functional CXCR7 is also expressed in synovial fibroblasts and that it plays a role in the 
induction of MMP production via CXCL12. Based on our data we hypothesize that while 
CXCR4 might be responsible for CXCL12 mediated cell trafficking into RA joints, CXCR7 
mediates CXCL12 signaling in resident synovial fibroblasts. The exact mechanism of 
signaling after binding of CXCL12 to CXCR7 is not clear yet [9, 46].  Recent studies found 
an association between CXCR7 and the adaptor protein β-arrestin2 [48-50]. Interactions of 
arrestins with different receptors have been shown to facilitate activation of the MAPK 
cascade, a signaling pathway which is known to regulate also MMPs [51].  
 
High production of MMPs by RASFs has been identified as major mechanism of joint 
destruction in RA [52]. In particular, MMP-1 and MMP-13 were reported to play a crucial 
role in the invasive properties of RASF as shown in the SCID mouse co-implantation model 
[53, 54]. Expression of MMPs is regulated by multiple pathways. DNA hypomethylation 
modulates expression of different MMPs in cancer cells. In OA chondrocytes the 
adipocytokine leptin has not only been found to be upregulated by promoter DNA 
hypomethylation but also to stimulate expression of MMP-13 [55]. Also, a variety of 
cytokines and chemokines stimulate the expression of MMPs [56, 57]. The chemokine 
CXCL12 was reported to induce the expression of MMP-3 in chondrocytes and of MMP-9 in 
osteoclasts [16, 27]. Furthermore, increased gelatinase and collagenase activity was described 
after CXCL12 stimulation in synovial fibroblasts [28]. Our present data suggest that the 
increased collagenase activity after CXCL12 stimulation stems from increased transcription 
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of MMP-1 and MMP-13. On the other hand, CXCL12 stimulation neither changed the 
quantity of MMP-2 nor of MMP-9 transcripts, pointing to indirect regulation of gelatinase 
activity by CXCL12. Since MMP-3 was described to contribute to the activation of pro-
MMP-9 and we found that MMP-3 is more abundant in CXCL12 stimulated cells, it is 
probable that CXCL12 increases gelatinase activity via upregulation of MMP-3 [58, 59]. 
Based on the differential induction of specific MMPs after stimulation with CXCL12 it can be 
concluded that CXCL12 does not induce MMPs via the Activator Protein-1 (AP-1), since all 
of the measured MMPs contain an AP-1 site in their promoter regions. Differences among the 
MMP promoters have been described and include not only binding sites for different 
transcription factors but also variability in the number and arrangement of binding sites, 
which strongly increases the complexity of MMP regulation [60]. 
 
In summary, our data show that basal expression of the chemokine CXCL12 is increased in 
RASF due to a defect in gene regulation by DNA methylation. In RA joints, accumulated 
CXCL12 produced by RASF might lead to increased expression of MMPs which mediate 
joint destruction. In addition to the previously reported global hypomethylation, we identified 
CpG island specific hypomethylation of CXCL12 which is involved in the intrinsic activation 
of RASF and thereby in the perpetuation of RA.  
   Chapter 3                                                         Karouzakis E. et al. Genes and Immunity 2011 
 
 
89
5. References 
 
1. Ospelt, C. and S. Gay, The role of resident synovial cells in destructive arthritis. Best 
Pract Res Clin Rheumatol, 2008. 22(2): p. 239-52. 
 
2. Karouzakis, E., et al., DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. 
Arthritis Rheum, 2009. 60(12): p. 3613-22. 
 
3. Wade, P.A., Methyl CpG-binding proteins and transcriptional repression. Bioessays, 
2001. 23(12): p. 1131-7. 
 
4. Reik, W., W. Dean, and J. Walter, Epigenetic reprogramming in mammalian 
development. Science, 2001. 293(5532): p. 1089-93. 
 
5. Hewagama, A. and B. Richardson, The genetics and epigenetics of autoimmune diseases. 
J Autoimmun, 2009. 33(1): p. 3-11. 
 
6. Esteller, M., Epigenetics in cancer. N Engl J Med, 2008. 358(11): p. 1148-59. 
 
7. Petit, I., D. Jin, and S. Rafii, The SDF-1-CXCR4 signaling pathway: a molecular hub 
modulating neo-angiogenesis. Trends Immunol, 2007. 28(7): p. 299-307. 
 
8. Kucia, M., et al., CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol 
Histol, 2004. 35(3): p. 233-45. 
 
9. Burns, J.M., et al., A novel chemokine receptor for SDF-1 and I-TAC involved in cell 
survival, cell adhesion, and tumor development. J Exp Med, 2006. 203(9): p. 2201-13. 
 
10. Raggo, C., et al., Novel cellular genes essential for transformation of endothelial cells by 
Kaposi's sarcoma-associated herpesvirus. Cancer Res, 2005. 65(12): p. 5084-95. 
 
11. Miao, Z., et al., CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is 
expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A, 2007. 104(40): p. 
15735-40. 
 
12. De Paepe, B., et al., Localization of the alpha-chemokine SDF-1 and its receptor CXCR4 
in idiopathic inflammatory myopathies. Neuromuscul Disord, 2004. 14(4): p. 265-73. 
 
13. Gu, J., et al., A 588-gene microarray analysis of the peripheral blood mononuclear cells 
of spondyloarthropathy patients. Rheumatology (Oxford), 2002. 41(7): p. 759-66. 
 
14. Krumbholz, M., et al., Chemokines in multiple sclerosis: CXCL12 and CXCL13 
upregulation is differentially linked to CNS immune cell recruitment. Brain, 2006. 129(Pt 
1): p. 200-11. 
 
15. Kryczek, I., et al., Stroma-derived factor (SDF-1/CXCL12) and human tumor 
pathogenesis. Am J Physiol Cell Physiol, 2007. 292(3): p. C987-95. 
 
   Chapter 3                                                         Karouzakis E. et al. Genes and Immunity 2011 
 
 
90
16. Kanbe, K., K. Takagishi, and Q. Chen, Stimulation of matrix metalloprotease 3 release 
from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC 
chemokine receptor 4. Arthritis Rheum, 2002. 46(1): p. 130-7. 
 
17. Nanki, T., et al., Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions 
play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J 
Immunol, 2000. 165(11): p. 6590-8. 
 
18. Burger, J.A., et al., Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a 
stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest, 
2001. 107(3): p. 305-15. 
 
19. Nanki, T., et al., Chemokines regulate IL-6 and IL-8 production by fibroblast-like 
synoviocytes from patients with rheumatoid arthritis. J Immunol, 2001. 167(9): p. 5381-5. 
 
20. Blades, M.C., et al., Stromal cell-derived factor 1 (CXCL12) induces monocyte migration 
into human synovium transplanted onto SCID Mice. Arthritis Rheum, 2002. 46(3): p. 824-
36. 
 
21. Watanabe, N., et al., Gene expression profile analysis of rheumatoid synovial fibroblast 
cultures revealing the overexpression of genes responsible for tumor-like growth of 
rheumatoid synovium. Biochem Biophys Res Commun, 2002. 294(5): p. 1121-9. 
 
22. Arnett, F.C., et al., The American Rheumatism Association 1987 revised criteria for the 
classification of rheumatoid arthritis. Arthritis Rheum, 1988. 31(3): p. 315-24. 
 
23. Ospelt, C., et al., The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 
decreases the expression of CXCR3 ligands. Ann Rheum Dis, 2007. 
 
24. Li, L.C. and R. Dahiya, MethPrimer: designing primers for methylation PCRs. 
Bioinformatics, 2002. 18(11): p. 1427-31. 
 
25. Bock, C., et al., BiQ Analyzer: visualization and quality control for DNA methylation data 
from bisulfite sequencing. Bioinformatics, 2005. 21(21): p. 4067-8. 
 
26. Distler, J.H., et al., The induction of matrix metalloproteinase and cytokine expression in 
synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S 
A, 2005. 102(8): p. 2892-7. 
 
27. Grassi, F., et al., CXCL12 chemokine up-regulates bone resorption and MMP-9 release by 
human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of 
rheumatoid arthritis patients. J Cell Physiol, 2004. 199(2): p. 244-51. 
 
28. Garcia-Vicuna, R., et al., CC and CXC chemokine receptors mediate migration, 
proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes 
from rheumatoid arthritis patients. Arthritis Rheum, 2004. 50(12): p. 3866-77. 
 
29. Kanbe, K., et al., Synovectomy reduces stromal-cell-derived factor-1 (SDF-1) which is 
involved in the destruction of cartilage in osteoarthritis and rheumatoid arthritis. J Bone 
Joint Surg Br, 2004. 86(2): p. 296-300. 
 
   Chapter 3                                                         Karouzakis E. et al. Genes and Immunity 2011 
 
 
91
30. Kondo, Y. and J.P. Issa, Epigenetic changes in colorectal cancer. Cancer Metastasis Rev, 
2004. 23(1-2): p. 29-39. 
 
31. Lin, C.H., et al., Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer 
Res, 2001. 61(10): p. 4238-43. 
 
32. Herman, J.G. and S.B. Baylin, Gene silencing in cancer in association with promoter 
hypermethylation. N Engl J Med, 2003. 349(21): p. 2042-54. 
 
33. Weisenberger, D.J., et al., Analysis of repetitive element DNA methylation by MethyLight. 
Nucleic Acids Res, 2005. 33(21): p. 6823-36. 
 
34. Roman-Gomez, J., et al., Promoter hypomethylation of the LINE-1 retrotransposable 
elements activates sense/antisense transcription and marks the progression of chronic 
myeloid leukemia. Oncogene, 2005. 24(48): p. 7213-23. 
 
35. Richardson, B., Primer: epigenetics of autoimmunity. Nat Clin Pract Rheumatol, 2007. 
3(9): p. 521-7. 
 
36. Lu, Q., A. Wu, and B.C. Richardson, Demethylation of the same promoter sequence 
increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. 
J Immunol, 2005. 174(10): p. 6212-9. 
 
37. Kaplan, M.J., et al., Demethylation of promoter regulatory elements contributes to 
perforin overexpression in CD4+ lupus T cells. J Immunol, 2004. 172(6): p. 3652-61. 
 
38. Oelke, K., et al., Overexpression of CD70 and overstimulation of IgG synthesis by lupus T 
cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum, 2004. 50(6): 
p. 1850-60. 
 
39. Calonge, E., et al., c/EBPbeta is a major regulatory element driving transcriptional 
activation of the CXCL12 promoter. J Mol Biol, 2010. 396(3): p. 463-72. 
 
40. Ceradini, D.J. and G.C. Gurtner, Homing to hypoxia: HIF-1 as a mediator of progenitor 
cell recruitment to injured tissue. Trends Cardiovasc Med, 2005. 15(2): p. 57-63. 
 
41. Garcia-Moruja, C., et al., Functional characterization of SDF-1 proximal promoter. J Mol 
Biol, 2005. 348(1): p. 43-62. 
 
42. Bradfield, P.F., et al., Rheumatoid fibroblast-like synoviocytes overexpress the chemokine 
stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of 
CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum, 2003. 48(9): p. 
2472-82. 
 
43. del Rey, M.J., et al., Human inflammatory synovial fibroblasts induce enhanced myeloid 
cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 
1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. 
Arthritis Rheum, 2009. 60(10): p. 2926-34. 
 
44. Pablos, J.L., et al., Synoviocyte-derived CXCL12 is displayed on endothelium and induces 
angiogenesis in rheumatoid arthritis. J Immunol, 2003. 170(4): p. 2147-52. 
   Chapter 3                                                         Karouzakis E. et al. Genes and Immunity 2011 
 
 
92
 
45. Law, N.M. and S.A. Rosenzweig, Characterization of the G-protein linked orphan 
receptor GPRN1/RDC1. Biochem Biophys Res Commun, 1994. 201(1): p. 458-65. 
 
46. Balabanian, K., et al., The chemokine SDF-1/CXCL12 binds to and signals through the 
orphan receptor RDC1 in T lymphocytes. J Biol Chem, 2005. 280(42): p. 35760-6. 
 
47. Infantino, S., B. Moepps, and M. Thelen, Expression and regulation of the orphan 
receptor RDC1 and its putative ligand in human dendritic and B cells. J Immunol, 2006. 
176(4): p. 2197-207. 
 
48. Zabel, B.A., et al., Elucidation of CXCR7-mediated signaling events and inhibition of 
CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol, 
2009. 183(5): p. 3204-11. 
 
49. Kalatskaya, I., et al., AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol 
Pharmacol, 2009. 75(5): p. 1240-7. 
 
50. Rajagopal, S., et al., Beta-arrestin- but not G protein-mediated signaling by the "decoy" 
receptor CXCR7. Proc Natl Acad Sci U S A. 107(2): p. 628-32. 
 
51. Gurevich, E.V. and V.V. Gurevich, Arrestins: ubiquitous regulators of cellular signaling 
pathways. Genome Biol, 2006. 7(9): p. 236. 
 
52. Konttinen, Y.T., et al., Analysis of 16 different matrix metalloproteinases (MMP-1 to 
MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid 
arthritis. Ann Rheum Dis, 1999. 58(11): p. 691-7. 
 
53. Jungel, A., et al., Effect of the oral application of a highly selective MMP-13 inhibitor in 
three different animal models of rheumatoid arthritis. Ann Rheum Dis, 2010. 69(5): p. 
898-902. 
 
54. Rutkauskaite, E., et al., Ribozymes that inhibit the production of matrix metalloproteinase 
1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum, 
2004. 50(5): p. 1448-56. 
 
55. Iliopoulos, D., K.N. Malizos, and A. Tsezou, Epigenetic regulation of leptin affects MMP-
13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis 
therapeutic intervention. Ann Rheum Dis, 2007. 66(12): p. 1616-21. 
 
56. Roach, H.I., et al., Association between the abnormal expression of matrix-degrading 
enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in 
the promoter regions. Arthritis Rheum, 2005. 52(10): p. 3110-24. 
 
57. Couillard, J., et al., The role of DNA hypomethylation in the control of stromelysin gene 
expression. Biochem Biophys Res Commun, 2006. 342(4): p. 1233-9. 
 
58. Ogata, Y., J.J. Enghild, and H. Nagase, Matrix metalloproteinase 3 (stromelysin) activates 
the precursor for the human matrix metalloproteinase 9. J Biol Chem, 1992. 267(6): p. 
3581-4. 
 
   Chapter 3                                                         Karouzakis E. et al. Genes and Immunity 2011 
 
 
93
59. Goldberg, G.I., et al., Interaction of 92-kDa type IV collagenase with the tissue inhibitor 
of metalloproteinases prevents dimerization, complex formation with interstitial 
collagenase, and activation of the proenzyme with stromelysin. J Biol Chem, 1992. 
267(7): p. 4583-91. 
 
60. Benbow, U. and C.E. Brinckerhoff, The AP-1 site and MMP gene regulation: what is all 
the fuss about? Matrix Biol, 1997. 15(8-9): p. 519-26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 4                                                                                                                Conclusion                           
 
 
94
 
 
 
 
 
Chapter 4: Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 4                                                                                                                Conclusion                           
 
 
95
 
For the first time, the methylation status of cells has been analysed in the synovial tissues of 
patients with rheumatoid arthritis (RA). RA synovial tissues were found to have 
hypomethylated nuclei (Chapter 2, Figure 1). Especially synovial fibroblasts had low amounts 
of 5-methylcytosine. RASF had hypomethylated repetitive sequences, such as the LINE-1 
promoter / 5’-UTR. Since no genetic polymorphism can explain the hyperactive phenotype of 
synovial fibroblasts to date, we hypothesised that the epigenetic modifications, particularly 
DNA methylation, can cause the activation of synovial fibroblasts and lead to joint 
destruction. When normal synovial fibroblasts were treated over a long period of time with 
the DNMT1 inhibitor 5-azacytidine (5-azaC), they overexpressed genes that are associated 
with joint destruction, such as matrix metalloproteinases, intergrins and others summarized in 
Chapter 2 (Suppl. Tables 1,2). These cells mimic RASF largely. 
 
DNA methylation has been extensively studied in cancer [1]. However, deregulation of the 
DNA methylation has also been observed in autoimmune [2], developmental [3] and 
psychiatric diseases [4]. In SLE, a global hypomethylation occurs in CD4 T cells [5]. Mice 
treated with 5-azaC developed autoreactive CD4 T cells that resemble lupus [6]. Bisulfite 
sequencing identified that the gene promoter of the CD11a integrin gene in lupus T cells and 
CD70 - the B-cells costimulatory molecule - in CD4 T cells from lupus patients were 
hypomethylated [7, 8]. Furthermore, global hypomethylation was described in SLE 
monozygotic discordant twins, the ribosomal genes being mostly affected by the 
hypomethylation of CpG islands [9].  
 
Deregulation of DNMTs has been suggested to cause global hypomethylation in various 
diseases. For example, T cells from SLE patients and monozygotic twins have reduced 
expression of DNMT1 [9, 10]. In RASF, we reported that the protein expression ratio of 
DNMT1 / proliferation nuclear antigen (PCNA) was decreased. In addition, pro-inflammatory 
cytokines further reduced the ratio of DNMT1/PCNA in stimulated cells. However, decreased 
DNMT1 may not be the only factor responsible for global DNA hypomethylation. A detailed 
investigation of the cellular DNA methylation pathway revealed a complex interplay between 
different enzymes and other proteins, such as methyl-binding proteins [11]. In addition, DNA 
methylation is linked to other metabolic pathways involving S-adenosylmethionine (SAM), 
i.e. the cells’ methyl donor. For example, two specific enzymes are involved in the formation 
of methionine, the precursor of SAM, and both can have an important influence on DNA 
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methylation, namely 1) methionine synthase (MS) that converts homocysteine into 
methionine, and 2) methylenetetrahydrofolate reductase (MTHFR) that catalyzes the 
conversion of 5,10-methylenetetrahydrofolate (5,10-Methylene-THF) to 5-
methyltetrahydrofolate (5-Methyl-THF), i.e. the cosubstrate for homocysteine remethylation 
to methionine (Figure 1). 
 
 
 
Figure 1: The folate and methylation pathways [12].  
 
 
The enzyme MTHFR is associated with the genetic mutation C677T in vascular diseases and 
RA [13, 14]. The mutation causes inhibition of its enzymatic function that alters its enzymatic 
activity and affects global DNA methylation [15]. Individuals homozygous to the mutation 
have high levels of homocysteine in their blood and lower amounts of DNA methylation. 
Mice with the MTHFR mutation developed hyperhomocysteinemia when these animals were 
fed with low or high methionine diet [16]. Abnormal high homocysteine levels occur in RA 
patients [17] and this has been associated with cardiovascular diseases [18]; thus, it would be 
important to investigate whether homocysteine levels are associated to polymorphisms of the 
MTHFR gene. Genotypic analysis of MTHFR has to be performed in the hypomethylated 
RASF. Global DNA hypomethylation was strongly correlated with elevated levels of 
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homocysteine in patients with uraemia [19]. Therefore, the possible association between a 
defect in the folate / methylation cycles and global DNA hypomethylation in RASF should be 
explored.  
 
Another hypothesis for the cause of global hypomethylation is a high rate of SAM 
consumption in RASF. SAM is also consumed by the cells during the synthesis of polyamines 
(putrescine, spermidine and spermine) [20]. The enzyme spermidine/spermine-N1-
acetyltransferase (SSAT1) recycles spermine and spermidine into putrescine [21]. The 
expression of this enzyme is upregulated with proinflammatroy cytokines such as IL-1 in 
RASF [22]. Furthermore, levels of putrescine are found elevated in the synovial fluids of RA. 
The urinary polyamines were significantly elevated in RA patients compared to controls [23]. 
Therefore, an overexpression of SSAT1 may result in an increased catabolism of polyamines 
and/or increased recycling of polyamines into putrescine, and in parallel is associated to a 
decreased cellular level of SAM. This hypothesis has to be proven experimentally.  
 
Reversal of DNA hypomethylation may reduce the activity of RASF and concomitantly of 
joint destruction. Therefore, a new therapeutic strategy should be developed to reverse DNA 
hypomethylation. The SCID mouse invasion model with RASF and normal cartilage can be 
used to investigate whether L-methionine or SAM can reverse RASF-mediated cartilage 
destruction. Previous research in humans and animals has used dietary supplements of 
vitamin B12, folate and L-methionine or SAM in the treatment of cancer and neurological 
disorders [24, 25].  
 
SAM is a natural compound that is not only the methyl donor of the cell, but also has been 
shown to block the demethylase activity of HEK293 cell and thus promote DNA 
hypermethylation [26]. Supplementation of breast cancer cells with SAM inhibits growth and 
metastasis [25]. SAM causes the hypermethylation of genes involved in breast cancer 
metastasis such as urokinase (uPA), myogenin in muscle cell differentiation and preselin 1 
(PSEN1) in amyloidogenesis [24, 25, 27]. 
 
Maternal nutrition plays an important role in the regulation of the epigenome as shown in the 
Avy (yellow agouti) mouse [28]. The agouti gene encodes for a paracrine signalling molecule 
which causes the yellow colour in the hair follicles of the agouti mouse. The gene expression 
of the agouti gene is regulated by an IAP transposable element upstream of its transcriptional 
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start site. IAP elements are usually methylated in the genome. In the agouti mouse, the degree 
of methylation in IAP mice varies dramatically, causing different coat colours. 
Supplementation of the female agouti mouse with methyl donating substances 2 weeks before 
pregnancy and during pregnancy alters the epigenome and colour of their offsprings [29]. 
Overall, the above observations in different mouse models and in disease supports that dietary 
supplementation with folic acid, vitamin B12 and L-methionine may reverse the methyl group 
metabolism and have a beneficial role in the treatment of RA patients. The possible beneficial 
effect of high methionine supplementation diets should be investigated in various animal 
models of arthritis.  
 
Finally, the characterisation of a specific gene target that was hypothesized to have altered 
DNA methylation in RASF was shown in Chapter 3. The activated RASF secrete chemokines 
that attract a variety of inflammatory cells into the joint. CXCL12 (SDF-1α) is a chemokine 
overexpressed by RASF. Our study reported that the promoter of CXCL12 is more 
hypomethylated in RASF than in normal OASF. The upregulation of CXCL12 can stimulate 
RASF, via the receptor CXCR7, to produce more matrix metalloproteinases (MMPs).  
 
Studies in RASF by other groups have shown that the apoptosis related death receptor 3 
(DR3) gene is hypermethylated and might be related with apoptosis resistance [30]. In 
addition, other investigators studied how interleukin-6 (IL-6) - a pro-inflammatory cytokine - 
is regulated by promoter DNA methylation in RA [31]. They found a specific CpG site to be 
hypomethylated in the promoter of the IL-6 gene in RA lymphocytes. Furthermore, the 
expression of EphrinB1 has been reported to be increased due to promoter hypomethylation in 
RASF [32]. In the future, a genome wide DNA methylation analysis using methylation 
immunoprecipitation and CpG island promoter tilling arrays should be performed comparing 
fibroblasts of different tissues and synovial fibroblasts of various patients [33]. The promoters 
of these genes that show differential methylation patterns can be then correlated with animal 
RA models and provide useful data for the pathogenesis of RA.  
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